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INTRODUCTION 
 
 
  Glaucoma is defined as a disturbance of the structural or functional integrity of 
the optic nerve that can usually be arrested or diminished by adequate lowering of 
IOP.(1) The term does not refer to a single disease entity, but rather to a group of 
diseases that differ in their clinical presentation, pathophysiology, and treatment. 
These diseases are grouped together because they share certain features, including 
cupping and atrophy of the optic nerve head, which has attendant visual field loss and 
is frequently related to the level of intraocular pressure (IOP).  
  The pathophysiology of glaucoma is a much- studied topic. Normal intraocular 
pressure is maintained by the production and drainage of aqueous humour, which 
circulates within the anterior chamber. The primary glaucomas are not associated with 
known ocular or systemic disorders that account for the increased resistance to 
aqueous outflow; the primary diseases are usually bilateral and probably reflect 
genetic predispositions.(2) Conversely, the secondary glaucomas are associated with 
ocular or systemic abnormalities responsible for elevated IOP; these diseases are often 
unilateral and acquired. Although many risk factors have been associated with the 
development of POAG – including thinner central corneal thickness, myopia, age, 
African or Hispanic race and diastolic perfusion pressure,  elevated IOP remains the 
most prominent factor – shared among the primary and secondary glaucomas – and 
the only factor that ophthalmic intervention can reliably modify. 
 That lowering the intraocular pressure can reduce the progression of glaucoma 
has been shown by multiple studies.(3,4) The Advanced Glaucoma Intervention Study  
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has shown that every 1 mm hg lowering of IOP reduces the risk of progression of 
glaucoma by 10%.  Hence lowering of the intraocular pressure through medical or 
surgical means remains the mainstay of glaucoma therapy. 
  The decision of primary surgical versus medical management would depend on 
a number of factors. For instance, patients who would be unlikely to respond 
adequately to conventional medical treatment, including those unavailable for follow-
up, unable to instil eye drops, or those with local ocular conditions that preclude the 
use of long-term topical medications (such as atopy or benign mucous membrane 
pemphigoid); patients  in whom a target IOP level is unlikely to be achieved with 
topical medications, because the baseline pressure lies at either end of the open-angle 
glaucoma spectrum (12-19 mm Hg or >35 mm Hg), and patients with visual  field loss 
such that any further progression would affect the patient's quality of life, would 
benefit from surgery as the primary intervention.(5) In a study done by Xiau H. et 
al(6) to evaluate the changes of optic disc parameters in primary open angle glaucoma 
patients after surgical and medical treatment, it was found that improvement in optic 
disc parameters occurred more commonly after surgical than medical treatment. The 
amount of reduction of IOP correlated with the extent of this improvement.  
  In normal individuals, IOP fluctuates 2 to 6 mmHg over a 24 hour period.(7) 
Drance(8) first characterized the diurnal patterns in IOP, and found that pressures 
were higher in the early morning than later in the day. Subsequent investigators 
examined the 24-hour pattern of IOP and found that nocturnal IOP was lower than 
diurnal IOP when measured in the sitting position.(9) However, when IOP is 
measured in the usual physiologic positions of sitting while awake and supine during 
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sleep, Liu and co-workers(10)  demonstrated that IOP was significantly higher during 
the nocturnal period than the diurnal period. Among individual subjects, two-thirds of 
glaucoma patients and over 90% of healthy controls had IOP peaks during the 
nocturnal period.(11) This diurnal variation in IOP Has been attributed to various 
causes, including postural variation,(12) circulating catacholamines(13) and increase 
in episceral venous pressure.  A study by Quaranta et al(14) found that the mean peak 
in IOP curves for young healthy individuals was found to occur in the early morning 
hours (between 5:30 AM and 6:30AM) depending on body posture.  Another study by 
Mansouri et al(15) for older healthy individuals at around 10:00 AM irrespective of 
body posture, while that in untreated glaucomatous patients was generally between 6 
AM and 10 AM.  
 In the eyes of patients with open angle glaucoma, the range of diurnal 
fluctuation has been found to be exaggerated to around 10 mm of Hg, or  even up to 
30-35 mm of Hg.(8,16) In a study conducted by Wilensky et al,(17) it was found that  
more than half of a group of patients with seemingly well controlled IOPs of 21 mm 
Hg or less in the office who were evidencing some progression of their visual field 
defects had pressure spikes greater than 22 mm Hg when diurnal curves were plotted 
using a self tonometer. Moreover, 50% of the time, the highest pressure was measured 
outside office hours. Another study conducted by Asrani et al(18)  employed self 
tonometry at home to arrive at similar conclusions. The study concluded that in 
patients with glaucoma with office IOP in the normal range, large fluctuations in 
diurnal IOP are a significant risk factor, independent of parameters obtained in the 
office.  
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  There are very few studies comparing the peak lowering effect of 
trabeculectomy versus that of topical anti glaucoma medication. One such study 
conducted by Ross AH et al(19) at the Bristol Eye Hospital, United Kingdom was an 
observational study, comparing a group of patients who underwent trabeculectomy 
and another group on medical management. It was concluded that although there was 
no significant difference between the IOP fluctuations among the 2 groups, the mean 
IOP was lower in the surgical group.  
  Another study conducted by Konstas et al(20) aimed to evaluate 24-hour 
intraocular pressure control in patients with moderate to severe open-angle glaucoma 
treated by trabeculectomy and mitomycin C versus maximum tolerated medical 
therapy. In a comparison of the diurnal IOP curves among the two groups, it was 
found that the surgical group had a lower peak and mean IOP, and also a significantly 
lower fluctuation of 24 hour IOP.The majority of peak IOPs (10 of 11) occurred 
outside of normal office hours. This study concluded that a well-functioning 
trabeculectomy provides a statistically lower mean, peak, and range of IOP for the 24-
hour day than maximum tolerated medical therapy in advanced glaucoma patients. 
 In spite of evidence that diurnal fluctuations in intraocular pressure  play an 
important role in the progression of glaucoma, this remains a topic of debate among 
glaucoma experts.(21) We conducted this study as very few studies,(20,22) and 
notably no studies comparing the diurnal intraocular pressure profiles in surgically 
and medically managed patients have been conducted in India.  
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AIM  
 
 
To compare the diurnal intraocular pressure profiles in patients with open angle 
glaucoma with intraocular pressure controlled on medical management (ocular hypotensive 
medication) versus those with intraocular pressure controlled following trabeculectomy.  
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OBJECTIVES 
 
 
Primary objectives: 
1. To compare the mean and peak intraocular pressures during a phased 24 hour 
recording of intraocular pressure in patients with open angle glaucoma with intraocular 
pressure controlled on medical management versus those with intraocular pressure controlled 
following trabeculectomy.    
2.  To compare the fluctuation of intraocular pressure variation during a phased 24 
hour recording of intraocular pressure in patients with open angle glaucoma with intraocular 
pressure controlled on medical management versus those with intraocular pressure controlled 
following trabeculectomy. 
Secondary obectives: 
1. To determine the timings of peak intraocular pressures in the two groups 
 2.  To plot and compare the diurnal intraocular pressure curves in the two groups  
 3. To measure supine nocturnal intraocular pressure using Tonopen and assess its 
significance.  
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REVIEW OF LITERATURE 
 
 
INTRODUCTION 
Glaucoma can be defined as a structural or functional disturbance in the 
integrity of the optic nerve that can usually be arrested or diminished by adequate 
lowering of IOP.(1) It is a chronic progressive optic neuropathy resulting in the 
gradual loss of peripheral vision and later, the central vision, leading to eventual 
blindness.(2) It is not a single disease, but rather a group of entities that share certain 
common pathological characteristics. The aetiology and pathogenesis of the 
glaucomas have been the subject of intensive study; however, they are yet to be fully 
understood.   
The open angle glaucomas may be classified as primary or secondary. Primary 
open angle glaucoma (POAG) is the commonest form of glaucoma in many countries. 
It was estimated that 45 million people suffered from this disease worldwide in the 
year 2010.(23)  Because POAG is a chronic, slowly progressive insidious disease, 
individuals are asymptomatic until very late in the disease course; hence they may 
seek help only in advanced stages of the disease.  Especially in developing countries, 
due to the scarcity of ophthalmological care and limited access, glaucoma is often 
diagnosed very late.(24) 
Multiple risk factors have been associated with primary open angle glaucoma, 
including older age,(25) African race(26), myopia, lower central corneal 
thickness(27),  family history of glaucoma(27), genetic factors(28),  and high 
intraocular pressure(27). Among all these, intraocular pressure has been identified as 
the only modifiable risk factor.  
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EPIDEMIOLOGY AND BURDEN OF DISEASE 
The glaucomas together constitute the second leading cause for blindness 
globally, following cataracts, and the leading cause for irreversible blindness.(29) The 
overall prevalence of glaucoma was around 3·5% for people aged 40–80 years, 
globally. This was estimated to be 64.3 million people in 2013, and is expected to rise 
to 76.0 million in 2020.(23)  Out of these, 56 million will be suffering from open 
angle glaucoma.  
 In India, different studies have been done to estimate the prevalence of 
glaucoma in the population. According to the Andhra Pradesh Eye Disease Study, the 
prevalence of Primary Open Angle Glaucoma (POAG) in a rural south Indian 
population was found to be 1.62%.(30) The Chennai Glaucoma Study was conducted 
among two groups- rural and urban; it was found that the Urban population had a 
higher prevalence of POAG (3.51%)  as compared to the rural population (1.62%). 
(31)The Vellore Eye Study found a prevalence of POAG of  0.41% and a higher 
prevalence of primary angle closure glaucoma of 4.32%.(32) The prevalence of angle 
closure glaucomas have also been found to be higher in Asians and Inuit Indians, 
However, in most other populations, open angle glaucomas have been found to be 
more prevalent.   
 Open angle glaucomas are characteristically symptomless- patients do not 
experience any ocular pain or vision loss in the earlier stages. They are either detected 
to have glaucoma incidentally, which may be relatively early in the course of disease, 
or, after vision loss is noticed by the patient, which may be at a much later stage when 
significant and irreversible glaucomatous damage has already occurred.  In developing 
 17 
 
countries, where a large fraction of the population is rural and the majority of 
healthcare facilities are concentrated in urban areas, access to healthcare for a large 
section of the population is very poor.  This leads to a delayed diagnosis of glaucoma 
and hence poor visual outcomes.(33) 
 
MECHANISM OF AQUEOUS SECRETION AND OUTFLOW 
 The aqueous humour is a transparent fluid secreted by the ciliary processes of 
the eye. This serves the primary role of nourishing the cornea and the crystalline lens, 
which are avascular structures. This constant nourishment and removal of wastes is 
necessary to maintain the transparency of the ocular media. There is a constant 
production and outflow of aqueous. The force responsible for the drainage of aqueous 
depends on the hydrostatic pressure across the outflow routes. The combination of 
aqueous secretion, aqueous outflow and resistance to aqueous outflow ensures a 
relatively high pressure within the globe, known as the intraocular pressure (IOP). 
This is a necessary requirement to maintain a stable globe, even with the traction 
forces exerted by the extra ocular muscles.(34) 
 The formation of aqueous involves two main steps. The first is ultrafiltration of 
the plasma through the semi permeable walls of the capillaries of the ciliary processes. 
This results in the formation of a scanty protein rich ultra filtrate which contains about 
60% of plasma protein. The second step involves active transport of sodium by the 
non pigmented layer of the ciliary processes. This is followed by an efflux of negative 
ions, including bicarbonate, from within the cell into the intercellular cleft. This 
results in a strong osmotic gradient which also results in the efflux of water molecules 
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into the extracellular space. Nutrients and other substances necessary for survival of 
the lens and cornea bypass the blood aqueous barrier and are transported by free or 
facilitated diffusion.(1),(34) 
 The normal rate of aqueous production was determined to be 2.75 + 0.63 
microliters per minute. The rate of aqueous flow also showed a distinct circadian 
rhythm, with the lowest flow of 1.2 microliters per minute seen between 12 midnight 
and 6 am. Other than the circadian rhythm, no other factors were found to 
significantly affect the pattern of aqueous secretion. (35) 
 
MEASUREMENT OF INTRAOCULAR PRESSURE 
 There are several available instruments for the measurement of intraocular 
pressure. They can be broadly classified into applanation instruments, indentation 
instruments, dynamic contour tonometry and instruments for the continuous 
measurement of IOP.(1) Applanation tonometry is the most commonly performed 
technique- the Goldmann Applanation tonometer being considered the gold standard 
in IOP measurement. The TonoPen is a portable applanation tonometer which 
provides a digital display of the measured IOP. Indentation tonometers include the 
Schiotz tonometer, which is not widely used now. Dynamic contour tonometry is used 
mainly in research settings. Contact lens sensors which measure IOP through the 
measurement of ocular dimensional changes have also been used in a few studies and 
provide a continuous recording of IOP.(36)  
 Studies have been performed to assess the comparability of different techniques 
of IOP measurement.  Bhartiya et al(37) conducted a study among 50 glaucomatous 
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and 130 normotensive eyes of a total of 180 patients comparing the IOP as measured 
by non contact tonometry (NCT), Goldmann applanation tonometry (GAT) and with 
TonoPen Avia (TPA). The limits of agreement (confidence interval 95%) for TPA–
GAT and TPA–NCT were +8.7 to −7.7 and +8.6 to −9.6 mmHg in the glaucomatous 
patients. In healthy subjects the limits were +4.8 to −5.1 and +6.2 to −5.2 mmHg, 
respectively. TPA was found to overestimate IOP compared to GAT in eyes with a 
central corneal thickness (CCT) greater than 520 μm and underestimate IOP in eyes 
with CCT less than 510 μm. 
 Another study by Kurtz et al(38) compared the IOP in patients with normal 
tension glaucoma as measured by three modalities- dynamic contour tonometry 
(Pascal-DCT), Goldmann applanation tonometry (GAT) and Tonopen XL. They 
found that the mean DCT IOP was higher than the mean GAT IOP by 3.07 mm, 
whereas the mean Tonopen IOP was lower than the mean GAT IOP by 0.7 mm Hg.  
 
INTRAOCULAR PRESSURE AND ITS VARIATION 
Normal range of intraocular pressure 
The intraocular pressure in healthy humans has been found to have a mean of 
15.5 mm Hg in large population based studies, with a standard deviation of 2.6 mm 
Hg. (39) Thus, the normal intraocular pressure has been defined to be a range two 
standard deviations above and below the mean, that is, 15.5 + 5.2 mm Hg, which is 
10- 21 mm Hg. Jonas et al,(40) conducted a study done in rural areas in Nagpur, 
central India. 9338 normal eyes of 4686 patients were tested. The age of patients 
ranged from 30 to 100. The mean IOP was found to be around 13.6 + 3.4 mm Hg.  It 
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must be remembered that although this has been defined as the “normal” range of 
intraocular pressure, in some patients, glaucomatous changes have been found even 
with pressures within this range.(41) Conversely, some individuals do not show any 
glaucomatous changes even with pressures higher than this range.(42) 
 
Variation of intraocular pressure 
The intraocular pressure is not maintained at a constant value; it has been found 
to fluctuate in both non glaucomatous and glaucomatous individuals. This was 
recognised as early as 1899, when Huguenin reported variation in tactile tension. This 
was confirmed by Maselnikov in 1904, using applanation tonometry. The dynamics of 
aqueous humour secretion and outflow have been studied extensively. It has been 
found in studies that the secretion of aqueous humour is reduced at night, even by up 
to 50%, and also that aqueous outflow is slightly reduced.(43) In spite of the 
significant reduction in aqueous outflow, repeated studies have revealed consistent 
peaks of IOP in the night time. There are different postulated mechanisms regarding 
the fluctuation of IOP. Thomassen(44) and Bain(45) showed that the nocturnal rise in 
IOP was precede by a recordable elevation in the epicleral venous pressure. Previous 
studies have shown that impairment of the sympathetic system abolishes the circadian 
rhythm of IOP, implication adrenergic stimulation in the fluctuation pattern. Other 
studies have shown that exposure to short wavelength light abolishes the IOP 
curve.(16)  Additionally, melatonin, which is secreted locally by the ciliary body with 
a night time peak, has also been postulated as a causative factor.(46) 
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Variation of intraocular pressure with posture 
An important factor that can change the IOP is body posture; generally, IOP 
measured in the sitting position is lower than that measured in supine position.  
A diurnal study performed by Chiquet and co-workers(47)  showed that sitting  
IOP  was  significantly  lower  than supine IOP, with a mean pressure difference of 
2.2 ± 2.9 mmHg  after  1 min and 1.9 ± 3.8 mmHg after 10 min of posture change. 
However, after performing similar measurements with a head lowering bed tilts, the 
eyes exhibited an eventual slight decrease of IOP of 1.3 mmHg as compared to the 
initial supine IOP. 
  In a study conducted by Liu et al(48), 24 hour IOP measurements were 
performed on 33 volunteers who were housed in a sleep laboratory for a 24 hour 
period under a controlled 16-h light and 8-h dark environment. The IOP was measured 
every 2 hours using a pneumatotonometer. In the first part of the study, IOP 
measurements were performed on 12 volunteers who were seated during the light-
wake period and in supine position during the dark  period . It was found that the 
nocturnal/supine IOP was higher than diurnal/seated IOP, with the 24 hour fluctuation 
of IOP as high as 8.2 ± 1.4 mmHg. This was initially thought to be due to a rise in 
episcleral venous pressure and redistribution of fluid in the supine position. However, 
in the latter part of the study, 24 hour IOP measurements were performed on 21 
subjects who were kept perpetually in supine position.  The mean IOP was still found 
to be higher in the dark period than the light period, showing that factors besides 
episcleral venous pressure were at play during the nocturnal period, causing the rise in 
IOP. This study also found that mean nocturnal   IOP measurements were higher as 
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compared to diurnal IOP levels, both in aging healthy patients and in untreated open-
angle glaucoma patients. 
 In another study by Liu et al(49), the phased 24 hour readings were performed 
on 18 healthy volunteers. The nocturnal IOPs were measured in sitting position to 
assess whether posture played a role in the occurrence of nocturnal peaks. It was 
found that night time IOPs showed peaks similar to those that occur in supine 
position. It was concluded that posture does not play a role in the occurrence of 
nocturnal IOP peaks. 
 Piven et al(50) conducted a study in 41 patients with untreated ocular 
hypertension or suspicious discs. The IOP was measured by Goldmann Applanation 
Tonometry in the seated position at 9 AM, 12 AM, 3 PM, and 6 PM; and in right 
lateral decubitus position around 12:15 PM. It was found that in 91.5% of eyes, the 
IOP was higher in lateral decubitus position. The right eye showed a raise in IOP of 
4.22±2.67 mm Hg and in the left eye, 3.51±3.11 mm Hg. This was significantly higher 
in the lower eye. The IOP was raised by2 to5 mm Hg in 67%of patients and 6 to 12 
mm Hg in 23.2% of patients. In the great majority of the eyes (80.5% RE and 78% 
LE) the lateral decubitus IOP was greater than maximal diurnal sitting IOP.  
 
Diurnal variation of IOP in normal individuals:   
Measurement of IOP (tonometry) over a 24 hour period comprises diurnal 
(daytime) and nocturnal (night time) readings. In most non glaucomatous individuals 
the IOP shows a diurnal range with peaks in the morning and troughs in the evening 
and night 
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In non glaucomatous individuals, IOP fluctuates during a 24 hour period  by 
around 4–6 mmHg.(51) In patients with ocular hypertension, the diurnal fluctuation is 
about 6–8 mmHg, but can reach as high a level of fluctuation as 15mm Hg. In 
glaucomatous individuals, the 24-h diurnal variation in IOP ranges between 6 and 15 
mmHg, but reaching up to about 40 mmHg in extreme cases.(52)  In most patients 
with glaucoma, 24 hour IOP studies have found that there is an early morning peak in 
IOP between 6:00 am and 12:00 pm.(53) This is accounted for by the fact that 
aqueous synthesis is significantly reduced at night, during sleep. However, IOP peaks 
can occur at any time of the day or night. This may also depend on the type of 
glaucoma and the number of measurements of IOP taken, with the greater number of 
IOP measurements giving a more accurate idea of the timing of the peak IOP. 
In a study done by Drance et al, the IOP of 404 normal eyes was measured 6 
times between 6:00 am and 10:00 pm. It was found that 16% had a range of IOP more 
than 6 mmHg, while 42% of patients showed a peak in IOP at 6:00 am. The mean 
range of IOP was  3.7 ± 1.8 mmHg.(54)  
In a similar study, Katavisto et al found that the highest IOP values were 
recorded at 8.00 am in 41% and at midnight in over 20% of 50 normotensive subjects.  
The mean 24 hour fluctuation of IOP was 3.17 mmHg.(55)  
In a study by David et al(16) diurnal IOP measurements were performed in 
healthy  eyes and 690 diurnal curves were analysed. It was found that 40.5% of 
subjects had an early morning peak, 22.6% at mid-morning, and 19% at mid day.  
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Newell and Krill et al(56) also studied a normotensive group of 30 individuals 
and found that the greatest frequency of peak IOPs were measured between 6:00 and 
8:00 am.  
 
RATIONALE FOR PERFORMING DIURNAL IOP STUDIES IN GLAUCOMA 
As stated earlier, intraocular pressure has been found to be the only modifiable 
risk factor for the prevention of progression of glaucoma. Hence, the mainstay of 
glaucoma therapy consists in lowering the intraocular pressure to a pre determined 
target intraocular pressure. (57)  The maintenance of the IOP within the target range 
of IOP is crucial to the management of glaucoma. The IOP is routinely assessed in 
outpatient settings by various methods of IOP measurement, such as Goldmann 
applanation tonometry, or the Tonopen. Older methods such as the schiotz tonometer 
are not used in most clinics now. IOP measurement usually involves a single of few 
measurements taken during office hours, initially before treatment to establish a 
baseline and after the initiation of treatment, to ascertain whether it is within the target 
range.  
Though measurement of IOP within office hours is time saving for the patient 
and the clinician, it must be remembered that one or a few IOPs do not reflect the IOP 
variations during the entire day. Since glaucomatous optic nerve damage can occur 
any time of the day, with fluctuations and peaking of IOP, it is important to ascertain 
whether the target IOP is being maintained throughout the day, and not merely office 
hours. The routine standard of care in most outpatient departments involves the 
measurement of one or a few IOPs during office hours; these cannot reflect the entire 
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IOP variation during a 24 hour period. Hence, this data would be insufficient to 
ascertain whether the target IOP is being met and maintained throughout the day, and 
thus, whether the treatment instituted is sufficient for the prevention of glaucomatous 
progression.  
In a study among 100 patients with primary adult onset open angle glaucoma 
by Arora et al(58), 24 hour IOP measurements were performed. The office hour 
fluctuation was found to be 4.31 ± 2.6 mm Hg, versus a 24 hour fluctuation of 7.03 ± 
2.69 mm Hg. The difference was found to be statistically significant. Two thirds of the 
patients were found to attain peak IOP outside office hours.  
A diurnal IOP profiling in patients before and after treatment would be useful 
in many ways: first, prior to treatment, it provides a good baseline, including a peak 
and a range of variation, giving the clinician an understanding of the IOP levels at 
which glaucomatous damage has occurred; second, this gives us an idea of the target 
IOP to be set. Though 24 hour IOP measurement is not widespread in mainstream 
clinical practice, it has recently roused interest in research circles, and, like the 24 
hour monitoring of blood pressure, has provided valuable data on the fluctuations of 
IOP in normal and glaucomatous individuals. 
Ideally, for each patient with glaucoma, performing a 24 hour IOP 
measurement would provide information regarding the baseline range and peak of IOP 
as well as the post treatment diurnal profile, and would aid us in setting target IOPs 
and assessing the efficacy of treatment. However, this is impractical, time consuming 
and expensive, and thus not a realistic strategy.  However, this can be overcome by 
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carrying out well designed studies in appropriate patient groups, and the results 
extrapolated to other patients with glaucoma.  
24 hour IOP studies have been used to study the efficacy of various anti 
glaucoma medications over the last decade. Most studies have stressed on the 
unreliability of single or office hour IOP measurements. Patients with an apparent 
well controlled IOP as per office hour measurements may have uncontrolled IOP 
peaks outside office hours. In a study conducted by Riva and coworkers(59)  the long-
term 24-h IOP control in travoprost-treated patients with POAG was assessed by 
performing repeated 24-h IOP measurements over a 5 year period while being treated 
with travoprost. It was found that the only predictors for treatment failure were the  
mean pre-treatment 24-h IOP and treated 24-h peak IOP during the 5 year follow-up 
period.  
 
VARIATION OF INTRAOCULAR PRESSURE IN OPEN ANGLE GLAUCOMA 
Several types of rhythms of intraocular pressure fluctuation have been 
described in glaucoma. Duke-Elder in 1954 described three types of curves in open 
angle glaucoma: a downward sloping curve with the peak soon after waking, seen in 
about 20 per cent patients, an upward sloping curve with the peak between 4:00 pm 
and 6:00 pm seen in 25 per cent cases, and a biphasic curve with a peak between 9:00 
am and 11:00 am, and a second peak between 4:00 and 6:00 pm seen in 55 per cent 
patients.  Other studies have also reported flat curves or irregular curves with frequent 
peaks, but these are rarer.(60)  
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The three main features of a 24 hour IOP profile are: (a) the mean IOP, (b) the 
range of IOP, and (c) the peak  IOP. Although the value of 24 hour IOP measurement 
in the long term treatment of glaucoma is yet to be proven, it has been found that those 
with uncontrolled IOP peaks show greater worsening. 
 In a study conducted by Asrani et al, Sixty-four patients (105 eyes with open 
angle glaucoma, on treatment, all of whom had office hour IOPs less than 25 mm Hg 
over a follow up period of 5 years,  performed home tonometry with a self-tonometer 
five times a day for 5 days. Although mean home IOP and baseline office IOP were 
similar (16.4 +/- 3.6 mm Hg and 17.6 +/- 3.2 mm Hg, respectively), the  IOP range 
over the 5 days of home tonometry was 10.0 +/- 2.9 mm Hg. The diurnal IOP range 
and the IOP range over multiple days were found to be significant risk factors for 
progression. The study concluded that large fluctuations of IOP were an independent 
risk factor for the progression of glaucoma, irrespective of baseline 
characteristics.(61)  
In a study by Konstas et al,(62) it was found that 45% of patients with 
exfoliation glaucoma and 22.5% of those with POAG showed a peaking of IOP 
outside of office hours. This re-emphasizes the need for the measurement of IOP 
outside office hours. 
It has been found in various studies that approximately two-thirds of the 
patients with untreated normal tension glaucoma (NTG) or untreated POAG attain a 
peak IOP in the morning. David et al.(16) performed a diurnal IOP study and recorded 
the highest IOP in the early morning hours in 40% of cases, while a further 25% of 
peak IOPs occurred before 12 pm. The trough IOP was not found to occur at any 
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particular time of the day. The mean range of IOP was 5.0 mmHg in normotensive 
subjects, 5.8 mmHg in glaucomatous individuals and 6.8 mmHg in ocular 
hypertensives.   
Wilensky et al.(12) studied 176 patients with POAG, 55 subjects with OHT and 
18 normal controls. Self-tonometry was successfully performed at home 5 times daily 
for 4 to 8 days with a pneumatootonometer. It was found that each of the groups had 
well defined IOP curves, and that the peak IOPs occurred in the morning or before 
midday.  
Similarly,  Sacca et al(63)  performed 2 hourly IOP measurements on 33 
healthy volunteers, 95 patients with POAG and 50 with NTG from 8:00 am to 8:00 
pm. The morning hours were found to show the maximum number of peak IOPs 
whereas the trough IOPs were found to occur in the afternoon. The daily IOP 
fluctuations were directly proportional to IOP levels. The fluctuations were higher in 
the POAG group (7% to 9.6%) than the control group (3.4% To 6.9%) and the NTG 
group (4.7% to 6.4%). 
Collaer and coworkers(64,65) studied 53 patients with NTG, 12 glaucoma 
suspects, and 28 patients with POAG and came to similar conclusions as the previous 
investigators. The characteristics of their diurnal IOP curve performed between 7:00 
am and 5:00 pm were similar in all 3 patient groups: higher IOP in the early morning, 
lower in the early afternoon, and a tendency for pressure to rise again at the end of the 
afternoon. In this study mean diurnal IOP fluctuation was 5 ± 2 mmHg. In a 
retrospective chart review study, diurnal IOP measurements of 68 untreated glaucoma 
suspects and 95 patients with NTG were performed at 10:00 am, 1:00 pm, 4:00 pm, 
 29 
 
7:00 pm, 10:00 pm, and 7:00 am. Again in the glaucoma suspects, the peak IOP was 
noted in the morning: at 7:00 am in the right eye and at 10:00 am in the left eye. The 
trough IOP was observed at 10:00 pm for both eyes. For both eyes of patients with 
NTG, the peak IOP occurred at 7:00 am and the trough IOP was measured at 10:00 
pm. 
 It has been found that the diurnal IOP variation between the two eyes in 
POAG is largely concordant. Dinn et al(66)  performed a diurnal IOP study on 93 
patients with POAG. IOPs were recorded at 10 am, 1 pm, 4 pm, 7 pm, 10 pm and 7 
am the next day. 56 of the 93 patients were treated with symmetric IOP lowering 
medication in the fellow eye, whereas 37 were not. They noted that the diurnal IOP 
curves exhibited parallel patterns in the fellow eyes. The IOP in the fellow eye at each 
time point was within 1.6 to 2 mm of the IOP in the treated eye. There was a 68 to 90 
% chance that the IOP in the fellow eye would be within 2 mm, and a 78 to 95% 
chance that the IOP in the fellow eye would be within 3 mm.  
 
DIURNAL VARIATION OF IOP IN MEDICALLY TREATED PATIENTS WITH 
OPEN ANGLE GLAUCOMA  
 Different classes of anti glaucoma medication have been used in open angle 
glaucoma and their effects on the circadian intraocular pressure studied.   
 
Prostaglandin analogues 
 Prostaglandin analogues are one of the most efficacious topical antiglaucoma 
medications available now. They act primarily by increasing the uveoscleral outflow, 
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and to a lesser extent, the trabecular outflow. (64) They have been found to achieve 
mean IOP reductions of 24 to 29%, with bimatoprost and travoprost showing greatsest 
efficacy.(51),(65) It has been shown that the peak IOP lowering effect of 
prostaglandins occurs 8 to 12 hours after administration.(67),(68) The once daily 
dosing of prostaglandin analogues makes it a convenient drug for patient use. 
 Latanoprost, a prostaglandin F2 alpha isopropyl ester prodrug, was the first 
commercially available drug in this class of antiglaucoma medication.  Several studies 
have been performed to evaluate its efficacy.  In a crossover trial by Orzalesi et al,(69) 
10 patients with POAG and 10 with Ocular Hypertension (OHT) were treated with 
timolol, dorzolamide and latanoprost for one month each, in randomized sequence. A 
24 hour IOP measurement was performed at baseline and after each month of 
treatment. It was found that all drugs reduced IOP significantly from baseline, except 
timolol at 3 am. It was found that latanoprost was more effective in lowering IOP than 
timolol and dorzolamide atmost time points. Also, latanoprost seemed to lead to fairly 
consistent lowering of IOP throughout the circadian cycle.  
 A similar study was performed by Quaranta et al,(70) where 27 patients with 
newly diagnosed POAG were treated with timolol 0.5%, brimonidine 0.2%, 
dorzolamide 2%, and latanoprost 0.005% for 6 weeks each with 4 week washout 
periods between change of medication. 2 hourly intraocular pressure measurements 
were performed at baseline and at the end of each 6 weeks of medical treatment. It 
was found that latanoprost had a mean 24 hour IOP after treatment of 16.62 ± 0.98 
mm Hg, which was significantly lower than eyes treated with timolol (17.63 ± 1.38 
mm Hg), brimonidine (18.32 ± 1.50 mm Hg), and dorzolamide ( 17.37 ± 1.47 mm 
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Hg). Although there was no significant difference in the IOP lowering efficacy of 
timolol and latanoprost during daytime hours, latanoprost was found to be more 
efficacious at wach 2 hourly time point between 10 pm and 6 am. The authors 
concluded that although timolol was comparable to latanoprost in lowering daytime 
IOP, latanoprost brought about a uniform reduction in circadian IOP especially with 
regards ro night time and early morning IOP.  
 The timing of administration of latanoprost is also thought to play a role in its 
IOP lowering efficacy.  Alm et al(71) conducted a 6 month randomized multicenter 
trial with 267 patients. Out of these, 89 patients received a daily dosage of latanoprost 
0.005% in the morning for 3 months, followed by in the evening for the next three 
months. 94 patients received the reverse schedule. Latanoprost applied in the morning 
was found to reduce the IOP from 25.5 to 17.7 mmHg (31%); and latanoprost applied 
in the evening, from 24.8 to 16.2 mmHg (35%). This difference was found to be 
statistically significant. It was concluded that latanoprost effected a greater reduction 
in IOP when administered in the evening.  
 In another study performed by Konstas et al(72), 33 patients with POAG were 
recruited and randomized to receive travoprost once a day, either in the morning or 
evening. After 8 weeks of treatment, a 24 hour IOP measurement was performed (4 
hourly readings starting at 6 am). The groups were then switched and diurnal IOP 
recorded at the end of 8 weeks. It was found that there was no difference in the mean 
24 hour IOP with morning or evening dosage of travoprost. However, evening dosed 
travoprost provided a better reduction of IOP at 10 am (17.2+/-2.1 mmHg) than did 
the morning dosing (19.1+/-2.5 mmHg). Moreover, evening dosing was found to have 
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a statistically lower 24-hour variation of IOP (3.2+/-1.0 mmHg) than morning dosing 
(4.0+/-1.5 mmHg), with similar safety in both groups. 
 The relative merits of different prostaglandin analogues have also been 
compared. Parrish at al(73) conducted a study to evaluate the daytime efficacy of 
latanoprost, bimatoprost and travoprost and compare all three. 410 patients with open 
angle glaucoma or ocular hypertension were included in this randomised double 
masked multicentre trial, held in 45 centres across the United States. At the end of 12 
weeks of treatment, daytime IOP was found to be similar in all groups. Hyperemia 
was reported with lower frequency in the group treated with latanoprost. 
 Yildirim et al(74) conducted a randomised double masked trial in 48 patients 
with newly diagnosed primary open angle glaucoma. 15 patients were randomised to 
receive 0.05% latanoprost, 16 to receive 0.04% travoprost, and 17 to bimatoprost 
0.03%, all as evening dosings. At the end of 8 weeks it was found that IOP levels were 
reduced 8.7 mm Hg at 8 am and 8.1 mm Hg at 10 am in patients treated with 
travoprost. Latanoprost-treated patients experienced 4.8 and 5.3 mm Hg reductions, 
whereas bimatoprost-treated patients experienced 5.5 and 4.9 mm Hg reductions at 
these time points. Travoprost was found to produce a significantly higher reduction in 
IOP at 8 and 10 am than did latanoprost and bimatoprost, but there was no significant 
difference at other time points. 
 However, in another multicentre randomized trial, Gandolfi et al(75) found 
contradicting results. 113 patients with POAG received bimatoprost and 119 received 
latanoprost (evening dosed) for 3 months. It was found that target IOP of less than 17 
mm Hg was attained more frequently in the group treated with bimatoprost  than with 
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latanoprost at the end of 3 months. Also, the mean 24 hour IOP was found to be about 
1 mm lower in the group treated with bimatoprost.  
 DuBiner et al(76) found similar results as the above study. In 64 patients with 
POAG, latanoprost or bimatoprost were administered in the evening for 29 days. 
Bimatoprost was found to reduce the IOP by 5.9-8.9 mm Hg, i.e., a 25-34% reduction, 
whereas latanoprost was found to bring about a 20-31% reduction, i.e., 4.4-7.9 mm 
Hg. The difference was found to be statistically significant. 
 The study done by Seibold et al(77) in patients with POAG or OHT recorded 
daytime and night time IOP readings in patients treated with travoprost with the 
sofZia preservative. 24 hour IOP readings were performed at baseline,  after 4 weeks 
of treatment and after discontinuation of the drug for 60 to 84 hours. It was found that 
the IOP was significantly lowered from baseline at each time point, and that the 
effects persisted throughout the 24 hour cycle even after 60 to 84 hours of 
discontinuation of the drug. However, in this study, travoprost lowered the IOP only 
by 16% in the daytime and 6% in the night time, with a mean 24 hour IOP lowering of 
12%. 
 Another study performed by Konstas et al(78) compared the effects of 
preservative free tafluprost versus preservative containing latanoprost in 38 eyes with 
OHT or POAG with baseline pressures between 24 and 32 mm Hg. Tafluprost was 
found to demonstrate similar mean 24 hour efficacy of IOP reduction as compared to 
latanoprost (17.8 versus 17.7 mm Hg). Latanoprost demonstrated significantly lower 
24 hour trough IOP (15.9 versus 16.3 mm Hg) whereas tafluprost was found to effect 
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a lower 24 hour IOP fluctuation (3.2 versus 3.8 mm Hg). There was no significant 
difference with respect to adverse effects among the two groups. 
 Bimatoprost is also available at a concentration of 0.01%. Tung et al(79) 
evaluated its efficacy in a study among 16 patients with POAG or OHT. Patients were 
housed in a sleep lab and underwent 2 hourly IOP measurements with a 
pneumotonometer in both sitting and supine positions during the 16 hour wake cycle, 
followed by 2 houly supine measuremens during 8 hours of the sleep cycle. They 
reported a 21.7% lowering of Iop during the daya ns 10.2% lowering during the night.  
 
Topical Beta Blockers 
 Timolol maleate is the most commonly used topical beta blocker. It acts by 
lowering the aqueous secretion. Timolol eyedrops are used in a concentration of 
0.25% or 0.5%, as a twice daily dosage. 
 Konstas et al(80) evaluated the IOP lowering effect of Timolol 0.5% in 38 
patients with POAG and 38 with pseudoexfoliation (PEX) glaucoma. It was found that 
the baseline IOPs were significantly higher at all time points with PEX glaucoma than 
in POAG in age matched patients. After treatment with timolol maleate, the reduction 
of the diurnal fluctuation of IOP was more pronounced in patients with PEX 
glaucoma(40%) than in patients with POAG (26%). Twenty-two (58%) of thirty eight 
patients with PEX glaucoma and twenty (53%) of thirty eight patients with POAG had 
peak IOP values outside office hours. Whereas twelve (32%) of the patients with 
POAG had IOP recordings of 18 mm Hg or less at all time points, only five (13%) of 
the patients with PEX glaucoma showed such IOP curves. The study concluded that 
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despite a greater initial IOP reduction in the patients with PEX glaucoma treated with 
timolol, this group still exhibited a higher IOP and significant fluctuation in the 
diurnal curve of IOP. 
 Orzalesi et al(69) in their crossover trial found that timolol was efficacious in 
lowering the daytime IOP, but had only half the IOP lowering effect at night (3 am). 
Quaranta et al(81) also reported that timolol was less efficacious during the night time, 
although its IOP lowering effect was comparable to that of latanoprost in the daytime. 
This observation has been attributed to the fact that beta blockers act by lowering 
aqueous secretion, which is physiologically lower at night time than during the day.  
To overcome the drawback of twice daily dosing, timolol maleate has also been 
formulated in the gel form.  This would allow for once daily dosing, freedom from 
preservatives and improved adherence. Shedden at al(82), in a randomized double 
masked multicentre trial, compared the efficacy of once daily dosing of timolol gel to 
a twice daily dosing of timolol solution.  286 patients with OAG were randomly 
assingned in a 2:1 ratio to the timolol gel group and the solution group. Diurnal IOP 
readings were measured at baseline, 2, 4, 8, 12 and 24 weeks. At the end of week 24, 
the mean reduction in IOP was found to be 5.6 to 5.9 mm Hg in the timolol gel group 
and  6.3 to 6.6 mm Hg in the timolol solution group. There was no significant 
difference in IOP among both groups with respect to the peak IOP. The timolol gel 
group, however, reported a more instances of blurring of vision and tearing than did 
the timolol solution group.  
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Quaranta et al(81) performed a similar masked crossover study in 28 patients 
with open angle glaucoma. Patients were treated with either 0.5% timolol solution or 
0.1% timolol gel for 2 months, and then switched over to the other arm for 2 months. 
The investigators reported a reduction in the mean 24-hour IOP from 23.1 ± 0.7 mm 
Hg at baseline to 18.9 ± 0.6 mm Hg after timolol 0.5% and 18.9 ± 0.8 mm Hg after 
timolol 0.1% hydrogel. Both formulations significantly decreased diurnal and 
nocturnal IOP, and the IOP at each time point, in a similar manner. 
There has been only one study by Nielsen et al(83) comparing the  effect of 
metoprolol 0.22 mg mounted on ophthalmic rods with timolol eye drops (0.5%). In 
this crossover study in 11 patients with open angle glaucoma, the authors reported 
similar diurnal efficacy in both these drugs. The mean IOP reduction was found to be 
26% in both groups.   
Topical Carbonic Anhydrase Inhibitors 
Carbonic anhydrase inhibitors bring about reduction in IOP by reducing the 
secretion of aqueous from the ciliary epithelium. The two commonly used medications 
in this class of drugs are dorzolamide hydrochloride 2% and brinzolamide 
hydrochoride 1%. Comparative studies between these two drugs have shown similar 
tolerability and efficacy in IOP lowering. In a study by Sall et al(84), in patients with 
PAOG and OHT, similar IOP lowering effects were found in three groups: IOP was 
lowered by 3.4 to 4.1  mm Hg (13.2% to 16.7%) with brinzolamide 1.0% administered 
twice a day; by 4.1 to 4.8 mm Hg (16.6% to 19.1%) with brinzolamide 1% 
administered thrice a day; and by 4.3 to 4.9 mm Hg (16.9% to 20.1%) with 
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dorzolamide 2.0% instilled thrice a day. Other studies have also found that 
dorzolamide monotherapy with a thrice daily dosage reduces the mean diurnal IOP by 
16to 26%.(85), (86) 
 Contrary to beta blockers (which also lower IOP by reducing aqueous 
secretion), carbonic anhydrase inhibitors have been found to have a better IOP 
lowering action at night time. The decreased nocturnal efficacy of beta blockers may 
be explained by the physiologically lower levels of circulating catacholamines during 
the night.(87) Orzalesi et al’s study(88) found that dorzolamide 2% in a thrice daily 
dosage was more effective at lowering IOP at midnight and 3 am than timolol 0.5%, 
although the latter showed a better IOP reduction in the evening hours. They also 
reported no statistically significant difference between the mean 24 hour IOPs among 
the two groups.  
 A randomized multicentre trial by Strahlman et al(89) compared the IOP 
lowering efficacy of dorzolamide 2% as a thrice daily dosage with that of 0.5% 
timolol maleate and 0.5% betaxolol hydrochloride, each administered twice daily. 523 
patients with POAG or OHT were recruited and followed up for one year. At the end 
of one year, the mean percent reduction in intraocular pressure at the daytime peak in  
2% dorzolamide, 0.5% timolol, and 0.5% betaxolol was approximately 23%, 25%, 
and 21%, respectively. At afternoon trough, the mean percent reduction in intraocular 
pressure was 17%, 20%, and 15% for dorzolamide, timolol, and betaxolol, 
respectively. This study, however, did not record night time IOPs. 
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 Stewart et al(51) in their meta analysis of24 hour efficacy of glaucoma 
medication, found that topical carbonic anhydrase inhibitors had a better night time 
than daytime efficacy.  IOPwas found to be reduced by an average of 16% during the 
daytime, and 21% during the night time, by a thrice daily dosage of  dorzolamide.  
Alpha Adrenergic Agonists 
 Brimonidine is a highly selective alpha 2 agonist which may be administered in 
a twice daily or thrice daily regimen. Stewart et al(90) in a study on 40 patients with 
POAG, found a mean reduction in IOP of 14 to 19% with brimonidine 0.2% 
administered thrice a day. Other studies(51), (91) found similar results.  
 Brimonidine, however, has been found to have decreased efficacy in lowering 
the night time IOP. Liu et al(92) in a study on 15 patients with OAG housedin a sleep 
laboratory, found that though brimonidine 0.2% in a twice daily dose led to a 
significant reduction in the daytime IOP by 12.5%, there was almost no reduction in 
the night time IOP. Orzalesi at al(88) reported similar findings, with minimal efficacy 
of brimonidine at 3 am and 6 am.  
 Konstas et al(93) in a crossover double blinder trial, evaluated the 24 hour 
efficacy of brimonidine 0.2% administered twice, or three times daily versus timolol 
maleate 0.5% given twice daily in patients with POAG. The mean 24 hour IOP for 
brimonidine twice daily and three times daily was 19.2 mmHg and 18.0 mmHg, 
respectively, whereas for timolol it was 17.7 mmHg. There was a statistically 
significant difference among all three groups. Moreover, pair-wise comparisons 
 39 
 
showed that thrice daily brimonidine or twice daily timolol reduced IOP more than 
twice daily brimonidine at every time point after 10:00 am. In contrast, thrice daily 
brimonidine and twice daily timolol were statistically similar over the 24 hour period, 
except at 4:00 pm when timolol maleate performed significantly better. This group of 
investigators also reported that three-times-daily brimonidine provided significantly 
better late afternoon and early nigh ttime efficacy than twice-daily dosing. 
Fixed combination therapies and their 24 hour efficacy 
 Most patients with glaucoma need more than one topical medication to reach 
the pre determined target IOP. According to the Lichter et al in the Collaborative 
Initial Treatment of Glaucoma Study (CIGTS)(94), 75% of patients with open angle 
glaucoma need 2 or more medications to reach target IOP. Fixed dose combinations, 
as compared to concomitantly administered antiglaucoma medication, have the 
advantaged of ease of administration, better compliance, and less exposure to 
preservative. However, there are few studies comparing the efficacy of these two 
groups.  
Combination of Carbonic Anhydrase Inhibitors with Beta Blockers 
 Stewart et al(51) in their meta analysis of clinical trials on the diurnal IOP 
reduction with anti glaucoma medication, reported a mean IOP lowering efficacy of 
26% for a fixed dose combination of dorzolamide and timolol.  
 In another randomized double masked multicentre trial by Feldman et al(95), 
230 patients with POAG or OHT were randomized to receive either a dorzolamide 
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2%/timolol 0.5% fixed dose combination (DTFC) twice a day, or timolol 0.5% twice a 
day. At the end of 8 weeks, the investigators reported a significant reduction in day 
time and night time IOP at all 8 time pointsin both groups; but the reduction with 
DTFC was significantly higher.  
 Eren at al(96) compared the effect of  dorzolamide 2%/timolol 0.5% fixed dose 
combination (DTFC) twice a day, with that of latanoprost 0.005%/timolol maleate 
0.5% fixed combination (LTFC) once a day on diurnal intraocular pressure (IOP) in 
33 patients with primary open-angle glaucoma. Patients were treated with each drug 
combination for 6 weeks, followed by a 6 week washout period and a crossover to the 
other arm. Diurnal 4 hourly IOP readings were performed at baseline and at the end of 
each 6 week period. Mean baseline IOP was 25.1 mm Hg. The investigators found a 
mean post treatment IOP of 16.3 mmHg with LTFC and 17.3 mmHg with DTFC. This 
difference was statistically significant.  
 Konstas et al(97) performed a 6 week crossover study to compare the 24 hour 
efficacy of latanoprost 0.005% versus DTFC. The mean 24 hour IOP for the DTFC 
group was 15.3 + 2.0 mm Hg, and for the Latanoprost group was 15.9 + 2.3 mm Hg. 
There was no significant difference in the mean IOPs among the two groups at any 
time point except at 10m, when the latanoprost group had an IOP of 16.6 + 3.1 mm 
Hg and the DTFC group had an IOP of 14.6 + 2.7 mm Hg.  
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Combination of Prostaglandin Analogues with Beta Blockers 
 Latanoprost 0.005% and timolol 0.5% fixed combination (LTFC) administered 
once a day was found to have a mean 24 hour IOP lowering efficacy of 33%.(51)  In a 
2 month crossover trial by Konstas et al(98), 34 patients with POAG were treated with 
timolol 0.5% twice a day, and LTFC as an evening dose. The diurnal IOP curves 
showed that LTFC was more efficacious than timolol at all time points. The mean 
baseline IOP was 25 mm Hg. After treatment with timolol, the 24 hour IOP mean was 
19.3 mm Hg, whereas after treatment with LTFC, the 24 hour mean was 16.4 mm Hg, 
the difference between which was statistically significant. Similar results were 
obtained in a later trial.(99) 
 The efficacy of timolol 0.5% and travoprost 0.04% fixed combination (TTFC) 
was evaluated in a 4 month crossover study by Konstas et al(100). This study 
compared the effects of evening versus morning administration of once daily TTFC in 
32 patients with either POAG or PEX glaucoma. Mean baseline 24 hour IOP was 
27.7 mmHg and both groups showed a highly significant IOP reduction at all time 
points. The authors reported that compared to morning dosing, the evening dosing of 
TTFC recorded significantly lower mean 24 hour IOP (18.4 versus. 19.2 mmHg) and 
significantly reduced 24 hour fluctuation (3.8 versus. 5.1 mmHg). 
Combination of Carbonic Anhydrase Inhibitor with Timolol 
 Tamer et al(100) in a randomized crossover trial in 36 patients with POAG 
treated with latanoprost monotherapy with resulting uncontrolled intraocular 
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pressures,  found an additional ocular hypotensive effect of 3.2 mmHg over 24 h when 
dorzolamide was added to latanoprost. Timolol was less effective over 24 h when 
added to latanoprost (2.6 mmHg). Importantly, when all time points were analyzed in 
this trial, dorzolamide was superior to timolol in five out of the eight time points 
evaluated. 
 Naksamura et al(101) in their randomised crossover trial in 20 patients received 
a combination of latanoprost with either dorzolamide or brinzolamide.  Both groups 
showed a significant reduction in IOP from baseline, and there was no statistically 
significant difference in reduction among the two groups.   
DIURNAL VARIATION OF IOP IN SURGICALLY TREATED PATIENTS 
 Surgery has been considered the mainstay of therapy, especially in advanced 
glaucomas. Although Laser trabeculoplasty is also a treatment modality for open angle 
glaucoma, with some studies showing that it is efficacious in reduction of IOP 
throughout the 24 hour period(102), (103), there are few studies proving the long term 
efficacy of this procedure. Also, 3 to 5 % of treated eyes may show a rise in IOP.(104) 
 Trabeculectomy has been found to be an efficacious and safe method of IOP 
lowering in most types of open angle glaucoma. It has been found to lower IOP tosafe 
and acceptable levels and also provide long term IOP control. A study by Saiz et 
al(105) in 26 eyes of 14 patients with open angle glaucoma compared diurnal IOP 
curves prior to treatment, one year after trabeculectomy and 5 years after 
trabeculectomy.  They reported a significantly lower IOP from baseline even at 5 
years, with a daytime diurnal range of 4.8 + 2.5 mm Hg.  
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 Gandolfi et al(106) in a prospective randomized control trial in 24patients with 
glaucoma and cataract, evaluated the effectiveness of trabeculectomy with 5 
fluorouracil versus trabeculectomy without the antimetabolite adjunct. At the end of a 
1 year follow up, 2 hourly daytime IOP was measured from 8 am to 6 pm. It was 
found that 10 of 12 eyes of the 5-FU group recorded a mean IOP of 15 mmHg or less 
at the end of 1 year as opposed to 1 of 12 eyes in the group without 5-FU. The IOP 
fluctuation was 10 to 17 mmHg in the 5-FU group and 14 to 22 mmHg in the control 
group. 
 Klink et al(107) compared diurnal and nocturnal IOP fluctuations before and 
after trabeculectomy in 35patients with POAG. The pre operative peak IOP was found 
to be 26.5 ± 5.9 mm Hg in the daytime and 23.4 ± 5.2 mm Hg at night time. At a 
followup after at least 300 days, the postoperative diurnal and nocturnal IOP peaks 
were 16 ± 4.4 and 16 ± 5.4 mm Hg, respectively. Pre- to postoperative IOP reductions 
were statistically different (day 40% and night 32%;). Diurnal fluctuation was reduced 
significantly from 12.1 ± 4.2 mm Hg preoperatively to 5.6 ± 2.2 mm Hg 
postoperatively (reduction of 54%), and nocturnal fluctuation from 7.1 ± 4.5 to 3.9 ± 
4.1 mm Hg (reduction of 46%), respectively. 
 In a similar study, Ross et al(22) analyzed the Diurnal IOP profiles in patients 
with open angle glaucoma, pre and post trabeculectomy, compared to a group of 
medically controlled patients. Fifteen eyes post trabeculectomy surgery served as the 
study group whereas a group containing 17 eyes controlled on topical antiglaucoma 
medication served as the control group. There was a statistically significant reduction 
in both mean IOP of 3.7 mmHg and peak IOP of 4.4 mmHg in the surgical group 
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compared to the medical group. There was no statistically significant change in the 
IOP fluctuation between the 2 study groups . 
 There are very few studies comparing the efficacy of surgical treatment versus 
medical treatment with regard to the circadian variation of IOP. Medeiros et al(108) in 
their study on IOP fluctuations during daytime hours, compared a group of 30 patients 
with POAG on antiglaucoma medication, with 30 eyes subjected to one or more 
trabeculectomies. All subjects were submitted to a day diurnal measurement of IOP 
from 8:10 am till 5 pm for every three hours, followed by the water drinking test. 
Although the mean post treatment IOP was similar among the two groups, the  IOP 
fluctuation were significantly higher in the medical group (3.2 + 1.5 mm Hg) than in 
the surgical group (2.2 + 1.7 mm Hg). The peak IOP was also lower in the surgical 
group.  A similar effect was seen following the water drinking test. From an overall 
baseline IOP of 10.6 mmHg, the mean IOP change following the WDT was 13% in 
the surgical group and 40% in the medical group.   
 Mansouri et al(109) compared the effect of latanoprost 0.05% versus 
trabeculectomy and deep sclerectomy in 60 prospectively recruited subjects with 
primary open-angle glaucoma. The medical group comprised 20 patients with 
controlled IOP (<18 mm Hg) with latanoprost 0.005% monotherapy and with no 
previous intraocular surgery or argon laser trabeculoplasty; the surgical groups 
included 20 patients after trabeculectomy, and 20 patients after deep sclerectomy with 
collagen implant (DSCI). They performed daytime IOP measurements and also IOP 
measurement after a water drinking test. The mean IOP was found to be lower in the 
trabeculectomy group (10.1 mm Hg) as compared to the DCSI group (13.7 mm Hg) 
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and the medical group (15.7 mm Hg). However, the IOP fluctuations were comparable 
among the three groups. Also, the medical group showed a higher elevation of IOP 
after the water drinking test (5.2 mm Hg) than did the DSCI group (3.8 mm Hg) and 
the trabeculectomy group (2.4 mm Hg). 
 Konstas et al(20) compared the 24 hour IOP curves in patients with advanced 
glaucoma, with seemingly controlled intraocular pressures after having undergone 
trabeculectomy with those who were controlled with maximal medical management. 
In this prospective trial conducted in a tertiary eye care centre in Greece, 60 patients 
above the age of 39, who had been diagnosed with either POAG or PEX glaucoma, 
and whose eye had been classified according to the advanced Glaucoma Intervention 
Study Visual Field classification score of 11 or more (moderate to severe damage) 
were enrolled. Patients in the medical group were phakic patients who had a 
controlled IOP (18 mm Hg or less during office hour visits) with 2 to 4 topical 
antiglaucoma medication of any class. Patients in the surgical group were phakic or 
pseudophakic patients who had undergone trabeculectomy with or without cataract 
surgery at least 6 months prior to recruitment. A well functioning bleb, the absence of 
any adjunctive antiglaucoma medication and absence of any otherprior surgical or 
laser procedures were also pre requisites for recruitment.  
 Patients in both groups were matched at the recruitment visit into pairs, based 
on an IOP within 1 mm Hg of each other at 10 am or within 1 hour. They were then 
hospitalized at the next visit to undergo diurnal IOP measurements using Golmann 
Applanation Tonometry by the investigators at 6 time points- 10am, 2 pm, 6 pm, 10 
pm, 2 am and 6 am. The IOP curves were then compared. 
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 It was found that a statistically lower mean IOP was observed in the surgical 
group ( 12.1 + 2.2 mm Hg) as compared to that in the medical group (13.5 + 2.0 mm 
Hg). The surgical group also exhibited a significantly lower IOP at each time point 
except 10am. The diurnal range (fluctuation) of IOP and the peak IOP were 
significantly lower in the surgical group.( During the IOP monitoring, no patients in 
the surgical group, and 11 patients in the medical group had an IOP of more than 18 
mm Hg at some time point.  The study concluded that in spite of seemingly well 
controlled IOP in medically managed patients with advanced glaucoma, undetected 
fluctuations with peaks pose a risk for progression of glaucoma.    
 A study by Matsuoka et al(110) in 14 eyes of 8 open angle glaucoma patients 
who had undergone combined trabeculotomy with sinusotomy, compared the pre and 
post operative intraocular pressure profiles. It was found that the post operative 
diurnal IOP curves showed a blunting of fluctuations, with significant reductions in 
the mean postoperative mean IOP (16.5±1.7 to 13.9±2.0 mm Hg) and the peak IOP 
(21.9±2.4 to 16.1±2.5 mm Hg).  
 In spite of significant differences in the diurnal IOP profiles between surgically 
and medically managed patients, very few such studies comparing the two groups 
have been undertaken. Specifically, in India, no such studies have been published. 
Hence this study was undertaken with the aim of comparing the effects of medical 
management versus surgical treatment on the control of IOP over a 24 hour period. 
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MATERIALS AND METHODS 
 
 
This was a prospective observational study conducted at the Department of 
Ophthalmology, Christian Medical College,Vellore. The study aimed to compare the peak 
intraocular pressure lowering effects as well as diurnal fluctuations of intraocular pressure  in 
patients who have attained target intraocular pressure following  trabeculectomy or by  ocular 
hypotensive medications.  
Patients who visited the General Outpatient Department (OPD) or the Glaucoma 
Clinic at the Department of Ophthalmology, Christian Medical College,Vellore who fulfilled 
the eligibility criteria were included in the study after informed consent. The two groups of 
patients included those with diagnosed open angle glaucoma, who had undergone 
trabeculectomy (isolated trabeculectomy or trabeculectomy with cataract surgery) and those 
on topical ocular hypotensive medication, who had attained 30% reduction from the original 
baseline IOP. This was determined from the office hour intraocular pressure measurements 
that were performed in the Outpatient department during routine follow up after the surgery 
or initiation of medical management.  
A questionnaire was administered to all participants of the study. Each participant was 
hospitalized for a 24 hour period as part of the study and underwent measurement of 
intraocular pressure (IOP) by the principal  investigator over a 24- hour period at four hour 
intervals( 6 am, 10 am, 2 pm, 6 pm, 10 pm and 2 am ). The IOP was measured with a  
Goldmann Applanation Tonometry (GAT) and with a Tonopen XL (Reichert, Inc.) in sitting 
position at 10 am, 2 pm, 6 pm and 10 pm and  in supine position with Tonopen  and sitting 
position with GAT at 2:00 am and 6:00 am. Diurnal tension curves were plotted for each eye 
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and the collated data analysed. The peak IOP, mean IOP and range of diurnal variation of IOP 
between the two groups were compared.  
The eligibility criteria for the study were as follows: 
• Above the age of 18 
• Diagnosed with open angle glaucoma   
• Should have undergone filtering surgery (trabeculotomy) or should have been 
started on ocular hypotensive medication at least three months prior to 
recruitment 
• Should be “controlled”, i.e., office measurement of intraocular pressure should 
be 30% from the initial baseline IOP prior to medical or surgical therapy  
 
Exclusion criteria included: 
• Patients unwilling to give informed consent/ unable to come for follow up 
visits 
• Patients with Normal Tension Glaucoma (NTG) defined as patients with 
baseline IOP ≤21mmHg with characteristic disc and field changes of open 
angle glaucoma 
• Pigmentary glaucoma  
• Patients who have undergone laser peripheral iridotomy  
• Patients who have been on steroid eye drops in the past three months 
• Pregnant or lactating women 
• Patients on systemic carbonic anhydride inhibitors  
 49 
 
• Patients who have undergone any ocular surgery besides uneventful cataract 
surgery and/or trabeculectomy 
• Patients with history of significant ocular trauma at any time 
• Patients with active ocular infection or inflammation 
• Patients who have not attained target intraocular pressure 
The primary outcome of the study was the comparison of the diurnal intraocular 
pressure profiles in patients with open angle glaucoma who had undergone 
trabeculectomy or were on topical ocular hypotensive medication, who are controlled 
as per office IOP measurements. 
Target IOP was defined as the intraocular pressure at which the clinician expects 
the ganglion cell death to be no greater than the age dependent rate, or the highest IOP 
at which no clinically apparent optic nerve damage occurs. It has varying definitions: 
• The collaborative normal tension glaucoma study (CNTGS) found that 
lowering of the IOP by 30% from the baseline was effective in slowing disease 
progression(111) 
• Many authors recommend maintaining an IOP range in the early teens, 
especially in advanced glaucomas(57) 
The various parameters considered in each diurnal curve were as follows: 
• The peak IOP was defined as the highest IOP recorded during a diurnal 
measurement, 
• The trough IOP was defined as the lowest IOP recorded during a diurnal 
measurement.  
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• The mean IOP was defined as The arithmetic mean of all IOPs recorded over 
the 24 hour period.  
• The diurnal fluctuation of IOP was defined as the difference between the peak 
and trough IOPs recorded during a diurnal measurement. 
Potential confounders in the study included age, gender, exercise, hypertension, 
systemic medication such as prostaglandins and vasodilators.  
Data regarding inclusion and exclusion criteria were obtained by a detailed history 
and clinical examination of the patients. Data regarding confounding factors were also 
obtained by a detailed questionnaire.  
Intraocular pressure was measured by Goldmann applanation tonometry using a 
Haag Streit slit lamp, which is the gold standard for IOP measurement, and 
additionally with a Tonopen XL in supine position at 2 am and 6 am.  Measurements 
were done by the principal  investigator.  
For the sample size calculation, the study “24 hour IOP Control with Maximum 
Medical Therapy compared with Surgery in Advanced Open Angle Glaucoma” by 
Konstas et al was used.  The average maximum IOP for the surgical group was 
13.4±2.3 mm Hg and medically treated patient group was 16.3±4 mm Hg according to 
this study. The sample size is calculated using nMaster software version 2.0. 
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Two Means - Hypothesis testing for two means 
 
Standard deviation in group  I 2.3 
Standard deviation in group  II 4 
Mean difference 4 
Effect size 1.27 
Alpha error (%) 5 
Power (1- beta) % 80 
1 or 2 sided 2 
Required sample size per group 10 
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With the mean difference of 4, alpha error of 5%, power 80% with the two sided test, 
the study required totally 20 patients in each arm, that is, a total of 40 patients. To 
prove the efficacy of surgery over medical management in lowering the peak IOP in 
open angle glaucoma, the study required a  total of  40 patients.   
 For continuous data such as age, the descriptive statistics n, Mean, SD, 
Median, IQR, Minimum and Maximum were calculated. For categorical data, the 
number of patients and percentage were calculated. The average IOP was calculated 
for each time point for both groups, and plotted to see the trend of diurnal variation. 
The mean and peak IOPs in the two groups were compared. The diurnal range or 
fluctuation of IOP was calculated for each patient and compared among the two 
groups. 
 The parametric t test was applied to see the mean difference between two 
groups (medically treated and surgical groups). The Chi-square test was applied to the 
data.  
 P-values were reported as specified by the statistical software used, at least 
up to three decimal places. P-values less than 0.0001 were reported as provided by 
statistical software (e.g. '<0.0001').All tests were two-sided at α=0.05 level of 
significance. All statistical analysis were done using SPSS software version 17.0. 
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RESULTS 
 
Demographic characteristics 
40 eyes of 22 patients were recruited for this study, 20 in the medical arm and 20 in 
the surgical arm. The medical group had 11 male and 9 female patients, whereas the surgical 
group had 7 male and 13 female patients. Both eyes were recruited in 19 patients. 
Table 1: Table showing the gender distribution of patients in the two groups  
 Medical group Surgical group 
Male 11 7 
Female 9 13 
Total 20 20 
 
Co- morbidities in participants  
Hypertension: 9 out of 22 patients recruited were hypertensive. 2 out of the 9 were on beta 
blockers whereas the rest were on treatment with calcium channel blockers. The medically 
treated group had more hypertensive patients than did the surgical group. 
Diabetes Mellitus: 8 patients recruited were diabetic, on oral hypoglycaemic agents. 16 of 
the eyes studied belonged to diabetic patients, out of which 10 were in the medical group and 
6 in the surgical group. None of the recruited patients had any diabetic retinopathy.  
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Baseline characteristics 
 40 eyes with Primary Open Angle Glaucoma (POAG) or Pseudoexfoliation glaucoma 
(PEX Glaucoma) were included in this study. Both surgical and medical groups had 18 eyes 
with POAG and 2 eyes with PEX Glaucoma.  
Table 2: Table showing the type of glaucoma in the recruited patients in the two groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Medical Group Surgical group 
POAG  18 18 
PEX glaucoma 2 2 
Total 20 20 
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Details of anti-glaucoma medications in the medical group 
 Among the eyes in the medical group, 6 patients were on a single ocular 
hypotensive medication whereas 14 were on combination therapy. The different drugs 
used were as given in the table below: 
Table 3: Table showing the number of patients on each combination of anti 
glaucoma medication 
Anti-glaucoma Medication  Number  Of patients 
Only Beta blocker 2 
Only prostaglandin analogue 4 
CA Inhibitor + Beta blocker 6 
CA Inhibitor + Beta blocker + PG Analogue 6 
CA Inhibitor + Beta blocker + PG Analogue + 
Alpha Agonist  
2 
Total 20 
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Baseline IOP characteristics: 
In both the medical and surgical groups, eyes in which 30% reduction or more from 
baseline IOP (IOP prior to treatment) had been achieved as noted from office hour IOP 
measurements (performed in the outpatient department) were recruited into the study. The pre 
treatment office hour IOP data was obtained from the previous outpatient chart 
documentation of the patients. The pre treatment and post treatment characteristics of IOP in 
the two groups are as given below. (Tables 4 and 5) 
Table 4: Table showing pre-treatment and post-treatment IOP in the two groups   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Medical group Surgical group P value 
Mean Pre treatment 
baseline IOP 
(mm Hg) 
27.00 + 4.63 32.00 + 4.94 0.773 
Mean Post treatment 
office hour IOP 
(mm Hg) GAT 
15.10  + 3.16 15.40 + 3.10 0.989 
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Table 5: Table showing reduction in IOP among the two groups 
 
 
 
 
 
 
There was no significant difference in the pre or post treatment baseline 
characteristics among the two groups of eyes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Medical group Surgical group P value 
Mean reduction in 
IOP (mm Hg) 
11.9 + 3.00 16.6 + 4.48 0.647 
% reduction in 
IOP 
43.99 + 7% 51.49 + 9% 0.880 
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Comparison of GAT and Tonopen intraocular pressures in the two groups: 
Table 6 shows the details of GAT and Tonopen IOP measurements at each time point. 
Table 6: Table showing Mean IOP as measured by GAT and Tonopen at each 
time point, in the two groups  
 Med GAT 
(mm Hg) 
Med Tono 
(mm Hg)  
P value Surg GAT 
(mm Hg) 
Surg Tono 
(mm Hg) 
P value 
10 am 15.25 ± 
3.46 
13.35 ± 
4.15 
0.940 12.45 ± 
2.41 
12.25 ± 
3.11 
0.995 
2 pm 15.35 ± 
2.30 
14.15 ± 
3.06 
0.860 12.70 ± 
2.38 
12.15 ± 
1.67 
0.970 
6 pm 14.7 ± 
2.65 
13.75 ± 
2.98 
0.460 12.65 ± 
2.32 
11.55 ± 
2.43 
0.985 
10 pm 14.8 ± 
2.11 
13.2 ± 
2.21 
0.851 12.95 ± 
3.42 
11.85 ± 
3.00 
0.896 
2 am 15.85 ± 
3.73 
14.35 ± 
3.54 
0.761 12.8 ± 
2.96 
11.95 ± 
2.93 
0.914 
6 am 16.5 ± 
3.33 
14.8 ± 
3.34 
0.362 12.6 ± 
3.32 
12.25 ± 
3.46 
0.970 
Med – Medical group;  Surg – Surgical group; GAT – Goldmann Applanation Tonometry    Tono- Tonopen 
There was no statistically significant difference in the IOP as measured by 
Tonopen and GAT. 
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Mean, peak and trough of the 24 hour IOPs among the two groups: 
Table 7 shows the mean, peak and trough of the 24 hour intraocular pressures in the 
two groups 
Table 7: Table showing the peak and trough of the 24 hour IOPs among the two 
groups 
 Medical group  Surgical group P value 
Mean pre recruitment 
IOP (mm Hg) 
15.10  + 3.16 15.40 + 3.10 0.989 
Mean 24 hour IOP 
(mm Hg) 
15.40 + 1.95 12.67 + 2.30 0.171 
Peak IOP (mm Hg) 18.65 + 2.39 15.05 + 2.98 0.237 
Trough IOP (mm Hg) 12.6 + 1.93 10.5 + 1.79 0.182 
 
 In the medically managed group, the peak IOP in the 24 hour period was found 
to be higher than in the surgically managed group. The mean IOPs also showed a 
similar trend, being lower in the surgical group, though these differences were not 
statistically significant. 
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Diurnal IOP (24 hour phasing) Curves 
The diurnal IOP variation at each time point were plotted  with the patient in seated 
position for both groups as measured by GAT (Figure 1)  
Figure 1: Plot showing the diurnal variation of mean intraocular pressure at 
each time point as measured by Goldmann Applanation Tonometry (in seated 
posture) in the medical group and the surgical group 
 
The medical group showed a peak in the early morning 6am recordings. The 
peak IOP was within 2 mmHg of the trough seen late evening. The surgical group 
showed almost similar IOP throughout the 24 hour phasing with no peaks or troughs. 
However the IOP in the surgical group was at all times lower than in the medical 
group.  
The mean IOP reduction in the surgical group was 43.99 + 7% as compared to 
51.49 + 9 % in the medical group. Hence we looked among those patients in the 
medical group, who achieved a reduction in IOP comparable to the surgical group 
(>50%). There were 4 such eyes and their diurnal variation curves were analysed and 
compared to the surgical group (Figure 2 ). 
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Figure 2: Graph showing the 24 hour intraocular pressure curves in the surgical 
group and those eyes in the medical group which had more than 50% reduction 
from baseline (GAT IOP measurements) 
 
 
 
The medical group still showed variation in IOP as compared to the surgical 
group. However their numbers were too small to make statistically significant 
conclusions. 
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Variation in IOP with posture  
Effect of posture on the diurnal (24 hour phasing) variation of IOP: 
IOP was recorded in supine position at the patient’s bedside   at 2am and 6am 
using Tonopen. To avoid inter device differences, the daytime IOP measurements 
with Tonopen  were considered for comparison and not the GAT measurements.The 
plotting of IOP with Tonopen at each time point is shown in Figure 3. 
Figure 3: Plot showing the diurnal variation of mean intraocular pressure at 
each time point as measured by Tonopen in the seated posture at 10 am, 2 pm, 6 
pm and 10 pm, and in the supine posture at 2 am and 6 am, in the medical group 
and the surgical 
group 
The medical group showed a peak in the early morning and a trough late 
evening. A small peak was noted at 2pm. The surgical group showed minimal 
variation through the 24 hours.  
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Comparison of the supine tonopen IOP and seated GAT IOP at 2am and 6am:   
The Tonopen mesurements were taken at 2am and 6am  in the supine position  
at the bedside followed by GAT IOP in the seated position 5 minutes later. The details 
in the medical group are shown in Figure 4 and and in the surgical group in Figure 5. 
Figure 4: Plot showing the night time and early morning variation of mean 
intraocular pressure as measured by GAT in the seated posture and with 
Tonopen in the supine posture at 2 am and 6 am, in the medical group  
 
 
In the medical  group (Figure 4), the plotting  of the  IOP in the seated position 
(GAT) and supine position (Tonopen) at 2am and 6am  showed   similar pattern  with 
the GAT seated IOP being slightly higher than the supine Tonopen IOP. This could be 
explained by the inter device difference rather than the posture.  As noted at the 
beginning (table 6) GAT tended to measure the IOP slightly higher than the Tonopen. 
Hence short term change in posture – seated GAT being measured 5 minutes after the 
supine Tonopen IOP  did not seem to affect the IOP. 
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Figure 5: Plot showing the night time and early morning variation of mean 
intraocular pressure as measured by GAT in the seated posture and with 
Tonopen in the supine posture at 2 am and 6 am, in the surgical group 
  
In the surgical group (Fig 5) both the supine tonopen IOP and seated GAT  IOP  
were almost similar. 
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Comparison of the fluctuation of 24 hour IOP among the two groups: 
Details of the fluctuation of IOP over 24 hours in the two groups are shown in 
Table 8. 
Table 8: Table showing the mean intraocular pressures and the mean fluctuation 
of intraocular pressure in the two groups over a 24 hour period (GAT readings) 
 Medical group Surgical group P value 
Mean 24 hour IOP 
 (mm Hg) 
15.40 + 1.95 
 
12.69 + 2.30 0.171 
Mean fluctuation 
24 hour variation  
(mmHg) 
6 + 1.97 4.25 + 1.91 0.129 
 
Though there was no statistically significant difference in the mean 24 hour 
IOP or the amount of variation in the IOP in the two groups, the mean IOP as well as 
the variation in IOP was lower in the surgical group as compared to the medical group  
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Comparison of the fluctuation of IOP in the two groups during office hours: 
Table 9 shows the details of the fluctuation of IOP in the two groups during 
office hours. 
Table 9: Table showing the mean intraocular pressures and the mean fluctuation 
of intraocular pressure in the two groups over office hours (10am, 2 pm and 6 
pm) 
 Medical group Surgical group P value 
Mean office hour IOP 
 (mm Hg) 
15.10 + 2.21 12.6 + 1.86 0.171 
Mean office hour fluctuation  
of IOP 
3.33 + 2.08 2.95 + 1.60 0.488 
 
There was no statistically significant difference when the office hour IOPs 
(measured at 10 am, 2 pm and 6 pm) were considered. However the surgical group 
trended to have lower IOP as well as lesser fluctuation as compared to the medical 
group. 
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Fluctuation of IOP during 24 hours in individual patients in the two groups:  
Figure 6 shows the details of the amount of fluctuation of IOP during 24 hours 
in the individual patients in the two groups 
Figure 6: Graph showing the 24 hour fluctuation of intraocular pressure in the 
medical and medical and surgical groups 
 
 
19 out of 20 in the surgical group had ≤ 6 mmHg variation in IOP. Only 1 had 
IOP variation as much as 10mm Hg.  
In comparison, 13 out of the 20 in the medical group had ≤ 6 mmHg variation 
in IOP. 7 patients had IOP fluctuation of more than 6mm Hg. 
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Fluctuation of IOP during office hours   in individual patients in the two groups:  
Figure 7 shows the details of the amount of fluctuation of IOP during office 
hours  in the individual patients in the two groups 
Figure 7: Graph showing the office hour fluctuation of intraocular pressure 
versus the number of patients in the medical and surgical groups 
 
Variations in office hour IOP recordings (10 am, 2 pm and 6 pm 
measurements) showed greater similarity among the two groups. Only 3 patients in 
the medical group and 1 patient in the surgical group showed office hour variations 
more than 6 mm Hg. 
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24 hour IOP fluctuations among patients in the medically treated group on 
different anti-glaucoma medications: 
Figure 8 shows the details 24 hour IOP fluctuations among patients in the 
medically treated group on the different anti-glaucoma medications 
Figure 8: The diurnal IOP fluctuation in the medical group among patients 
treated with different anti-glaucoma medications  
 
The numbers of patients of various anti-glaucoma medications were too small 
to make ant statistically significant conclusions. However, among these patients 
fluctuation of IOP was similar in patients on various anti-glaucoma medications 
except patients on topical CA inhibitor, beta blocker, PG analogue and alpha agonist. 
However there were only two patients on these medications. 
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DISCUSSION 
 
40 eyes of 22 patients were recruited for this study, 20 in the medical arm and 
20 in the surgical arm. There were more males in the medical group and females in the 
surgical group. This is unlikely to affect the outcome as gender has not been found to 
have any effect on open angle glaucoma.(1)  
Patients with Primary Open Angle Glaucoma (POAG) or Pseudoexfoliation 
glaucoma (PEX Glaucoma) were recruited in this study.  Patients with normal tension 
glaucoma (NTG) were not included in this study as the pathology in NTG is believed 
to be different from that in primary open angle glaucoma.  Perfusion of the optic nerve 
head and retinal nerve fibre layer is thought to play an important role in the 
pathogenesis of NTG. Also since the initial baseline pressures are lower in NTG, 
further evaluation of the variation in IOP after initiation of treatment may not yield 
statistically significant conclusions.  Systemic hypertension with nocturnal 
hypotension, migraine headaches and previous systemic blood loss are among 
important risk factors.(2) Systemic beta blockers are prone to cause nocturnal 
hypotension and thus play a role in the progression of normal tension glaucoma.(3) In 
this study, two patients with POAG on oral beta blockers have been recruited. 
However, only those with 30% reduction in IOP were recruited, and since patients 
were on anti hypertensive medication both prior to and after the initiation of treatment 
for glaucoma, the use of systemic anti hypertensive is unlikely to affect the outcomes 
of the study. 
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Both surgical and medical groups had 18 eyes with POAG and 2 eyes with PEX 
Glaucoma. Those on medical management were on various anti glaucoma medications, 
including topical carbonic anhydrase inhibitors, beta blockers, prostaglandin analogues, alpha 
agonists and various combinations of the above.  The numbers in each subgroup were too 
small for further sub- group analysis.  
The variation of intraocular pressure in glaucoma patients has been examined in 
various studies. Peaks in IOP outside office hours in nocturnal periods can go undiagnosed  in 
as many as 45% of patients.(4) Hence, we measured IOP variation by 24 hour phasing. The 
intraocular pressure (IOP) was recorded at 6 time points- 10 am, 2 pm, 6 pm, 10 pm, 2 am, 
and 6 am.  Goldmann Applanation Tonometry (GAT) was used for all measurements since it 
is the gold standard. However, Tonopen was used in addition to GAT during the 2am and 6 
am recordings since the habitual supine posture in this time interval may affect IOP. At 2am 
and 6am    Tonopen IOP was first measured at the patient’s bedside followed by seated GAT 
IOP measurement 5 miniutes later. The longer duration of supine position from around mid-
night to 6am  may affect the IOP rather than the  short durations of change in posture (as  
during measurement of supine Tonopen IOP and seated GAT IOP 5 minutes later in our 
study) as shown in some studies  (5,6). In order to ensure comparability, we also measured 
Tonopen IOP at each time point in the patient’s habitual position (seated). Also, since the 
daytime recordings were done using both GAT and Tonopen, with the patient in the same 
position, it allowed us to look for any inter device variation of IOP.   
 The pre treatment IOPs as well as the post treatment IOPs were similar in the 
two groups (Tables 4 and 5). Though the surgical group achieved greater reduction (51.5%) 
from the baseline IOP, as compared to the medical group (43.9%), the difference was not 
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statistically significant (p=0.880). Also, when a sub analysis was performed comparing the 
patients in the medical group who had achieved reduction in IOP similar to  the patients in  
surgical group,  there was no difference (Figure 2). However, the numbers are too small to 
achieve statistical significance.   
To assess inter device differences between GAT and Tonopen, we compared the IOPs 
measured by the two devices (Table 6). At all time points, there was no statistically 
significant difference between the two sets of measurements. However, at all time points, the 
Tonopen IOP was lower than GAT IOP in the medical group. In the surgical group, the 
values were nearly similar though Tonopen IOPs were slightly lower at fewer time points as 
compared to the medical group. We cannot provide any reason why the medical group had 
lower Tonopen IOP values. These values were seen not to be related to posture, since the 
daytime recordings also showed similar lower Tonopen values as compared to GAT. 
However none of these differences were statistically significant. 
The mean peak IOP was found to be higher in the medical group when compared to 
the surgical group. However, this difference was not statistically significant. Additionally, it 
was found that 15 patients in the medically managed group had a peak IOP of more than or 
equal to 18 mm Hg, as compared to 5 patients in the surgically managed group. A study by 
Konstas et al(7) comparing patients on topical anti glaucoma medication with those who had 
undergone trabeculectomy found similar results. In their study, 11 medically controlled 
patients and none of the surgically managed patients had a peak IOP > 18 mm Hg.   
The mean 24 hour IOP in the surgically managed group was slightly lower than that of 
the medical group. This could be due to the baseline in the surgical group itself being lower, 
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though this was not statistically significant. Similar findings have been reported in other 
studies.(7,16)  
 
 
On comparing the 24 hour phasing curves between the 2 groups, we found almost no 
fluctuation in IOP throughout the 24 hours in the surgical group (< 1 mm Hg). Though some 
studies(8,9) have shown less fluctuation with surgery as compared to medical management, 
such low fluctuations as seen in our study have not been reported. This could be explained 
probably due to the large IOP reduction in IOP achieved (50%) in the surgical group, though 
for recruitment into the study, the required IOP reduction from baseline was 30%.                  
It is to be noted that  the 24 hour curve was representative of the mean IOP of all patients  at 
each time point.   
On the other hand, the medical group showed peaks and troughs in the diurnal curve, 
with the maximum IOP being recorded at 6 am, and a smaller peak at 2 pm. This is similar to 
the early morning peaks described in a few other studies.(11) However, most other studies 
have shown a nocturnal peaking in IOP in patients on medical management.(12,13) It was 
also found in most studies that prostaglandins were probably the only class of medication that 
blunt the nocturnal peaks.(14,15) However, in our study, we did not have a pre treatment 
phased 24 hour recording which would have made better insight into the pattern of fluctuation 
prior to and after treatment. This was beyond the scope of the study, since the aim of the 
study was to compare the 24 hour IOP variations in surgically and medically treated patients.  
 Studies performed in patients with POAG have shown peaks in the early 
morning hours, followed by a trough and a second smaller peak later in the evenings. After 
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the initiation of medical management, it is likely that there is a persistence of the same 
pattern, albeit with a reduction in the IOP. However, this conclusion was derived from the 
graph representing the mean IOP value of all patients at each time point. On examining 
individual curves, it was found that out of the 20 patients in the medically managed arm, it 
was found that 5 patients had peak IOP at 6 am, and 5 at 2 am. It was also noted that 6 
patients in the medical group had very similar IOPs (within 1 mm Hg) at 2 am and 6 am.  
 
The fluctuation in each patient was calculated and the mean fluctuation arrived at. It 
was found that the fluctuation in the surgical group varied from 2.34 to 6.16 mm Hg, and the 
mean fluctuation was 4.25 mm Hg in the surgical group. Similarly, the range of fluctuation in 
the medical group was 4.03 to 7.97 mm Hg, with the mean being 6 mm Hg. Though the 
surgical group showed lesser fluctuation (Table 8), this was not statistically significant (p= 
0.129). On plotting the fluctuation during office hours, nocturnal hours and throughout the 24 
hour phasing curves in the groups, fewer patients had fluctuations > 6 mm Hg in the surgical 
group as compared to the medical group, though not statistically significant. (Figure 6) These 
values mirror those reported in other 24 hour IOP studies, for instance, those by Konstas et 
al(7) and Klink et al(16).  Also, for both the medical and surgical groups, the office hour 
fluctuations were found to be lower than the 24 hour fluctuations (Table 9). 
 It has been observed that there are nocturnal IOP peaks in glaucomatous 
patients. This could be due to various mechanisms- ocular perfusion, supine posture causing 
increased episcleral venous pressure, nocturnal hypotension, circulating catecholamines, etc. 
Even after the initiation of treatment, such nocturnal peaks have been seen with anti 
glaucoma medication.(17) In a study by Medeiros et al(9), no nocturnal peaks were found in 
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surgically treated patients. Studies have been performed in sleep labs. In our study we looked 
at the nocturnal IOP in supine position by recording the supine IOP measurements by 
Tonopen at 2 am and 6 am, during which time the patient would have been in recumbent 
position habitually.  
In our study too, we saw that in the medical group, the IOP tended to rise at night from 
10pm till the early morning peak at 6am (Figure 1). Hence the nocturnal rise persisted in the 
medical group. Thus it seems that in the medical group, though there is an overall reduction 
in IOP, the pattern of late night and early morning rise in IOPs which could be related to 
supine posture tended to persist. Also due to the small number of patients in each category of 
ant-glaucoma medications, subgroup analysis according to the different medications was not 
possible.  
This is in contrast to the surgical group where the IOP was low at all times with no rise 
in IOP noted at the nocturnal habitual supine position recordings. However since various 
mechanisms are involved in the pathogenesis of nocturnal spikes we can only conclude that 
surgery blunts the nocturnal rise- which could be related to posture. This is similar to that 
observed in  few other 24 hour phasing studies that have examined surgically managed 
patients, and found  that there is no nocturnal IOP peak.(7) .  
  We also looked at the seated GAT IOP measurements in all patients at 2am and 6am , 
taken 5 minutes after  the supine IOP measurements were taken with the Tonopen . The GAT 
recordings were similar to the Tonopen recordings though the GAT values were slightly 
higher that the corresponding Tonopen  measurements. This was similar to that seen during 
other similar recordings during daytime (Table 6), indicating inter device difference rather 
than the effect of short term change in  posture.   This suggests that prolonged postural 
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positions are required to affect IOP, and that short term changes in posture are unlikely to 
affect IOP.  
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SUMMARY AND CONCLUSIONS 
 
 
1. In patients with open angle glaucoma with adequately controlled intraocular 
pressures, the surgically managed patients showed lower peak and mean 
intraocular pressures during 24-hour phasing as compared to those on ant-
glaucoma medications. However these differences were not statistically 
significant. 
It was found that 15 patients in the medically managed group had a peak IOP 
of more than or equal to 18 mm Hg, as compared to 5 patients in the surgically 
managed group. 
 
2. During office hours as well as  24 hour phased IOP measurements, there was 
less fluctuation in IOP in the surgical group as compared to the medical group, 
though the difference was not statistically significant.  
On examining individual data, only 1 out of 20 patients in the surgical group 
had a diurnal fluctuation of more than 6 mm Hg, as compared to 7 patients in 
the medical group. 
 
3. The 24 hour IOP curve of the surgical group did not show any peak in the IOP 
at any time point throughout the 24 hour phased measurements. In the medical 
group, the 24 hour diurnal IOP plot showed higher IOPs during the nocturnal 
and early morning hours (2 am and 6 am).  
The trend to higher nocturnal and early morning pressure in the medical 
group could be due to their normal diurnal variation pattern which would likely 
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have been seen prior to treatment as well. This in turn could be related to 
posture or haemodynamic factors. It  is likely that the anti glaucoma 
medications have reduced the IOP overall, with  the fluctuation  pattern 
persisiting  post- treatment. Surgery seems to blunt any sort of diurnal variation 
which is expected in all patients including glaucomatous and normal 
individuals. But we could not find any plausible explanation for this and the 
exact mechanism needs to be elucidated. However, pre treatment diurnal curves 
were not available for comparison. 
 
4. Immediate or short term change in posture (as measured by supine IOP 
recordings with Tonpen followed 5 minutes later by GAT recordings in seated 
posture) did not affect IOP measurements. Hence GAT measurements taken 
during nocturnal hours after waking a patient from habitual supine position can 
be used for studying IOP recordings at these times.  
 
5. Similar to the low nocturnal IOPs seen in the surgical group in our study, few 
studies have reported low nocturnal IOPs in medically managed patients treated 
with prostaglandin analogues or fixed dose combinations of dorzolamide and 
timolol.  Subgroup analyses of patients on these medications were not possible, 
due to very small numbers in this study. Studies with larger numbers of patients 
in each subgroup would be needed for comparison of their 24 hour IOP profiles 
with the surgically managed group. 
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LIMITATIONS 
 
 
1. It would have been ideal to have the pre treatment baseline diurnal 24 hour phasing 
curves of medically and surgically controlled patients, for comparison post treatment.  
However, this was not planned as part of study design due to constraints of time. 
 
2. While performing nocturnal IOP measurements, measuring Tonopen IOP in the 
seated position at 2 am and 6 am would have been ideal (in addition to the supine 
Tonopen readings and seated GAT readings at the same timings). This would have 
ensured better comparability of the seated and supine IOP measurements.  
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INFORMATION SHEET  
 
 
Diurnal intra ocular pressure profiles in patients with open 
angle glaucoma who have undergone trabeculectomy versus 
those  on topical ocular hypotensive medications 
Name of participant:  
You are invited to take part in this study. The information in this document 
is meant to help you decide whether or not to take part in the study. Please 
feel free to ask if you have any queries or concerns.  
What is the study about?  
Glaucoma is a disease of the eye in which there is  damage to the nerve of 
the eye, causing gradual loss of vision from the sides of the eye or 
peripheries, also known as visual field defect. It does not usually have any 
symptoms in the early stages,  and is usually detected when the vision loss 
affects the centre of the retina, or macula. At this point the vision loss is 
irreversible. It is the second leading cause of blindness in the world and the 
leading cause of irreversible blindness. Multiple factors have been thought 
to play a role in the disease, but a raised intra-ocular pressure (IOP, or the 
pressure within the eye) has been found to be the only factor that can be 
changed. A reduction in IOP has been found to slow/stop the progression of 
the disease.  
Glaucoma can be treated with eyedrops or surgery. It has been found that 
intra-ocular pressure varies throughout the day in those with and without 
glaucoma. In patients with glaucoma, who have been treated with 
medication or surgery, normal follow up is done by checking IOP 
measurements in the hospital outpatient department (OPD). This may not 
give an accurate idea of the changes in pressure over the day. Hence, with 
your help, we would like to determine how much the IOP varies throughout 
the day. 
As a part of the study, you will be hospitalized for one day, during which 
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time the intraocular pressure will be checked in both eye, by two different 
methods, six times. You are advised to continue any routine medication you 
are on at this time. There may be minimal discomfort associated with this. 
In this study, we will check the intra-ocular pressures at regular intervals 
throughout the day in two groups of individuals with open angle glaucoma-  
those who are on anti glaucoma eye drops and those who have undergone 
surgery for pressure control. We hope to detect IOP peaks and the 
importance of variation of IOP in glaucoma progression, and to compare 
whether surgery or glaucoma medication is more effective in controlling 
the peak IOP.  
If you take part, what will you have to do?  
If you take part in the study, you will be asked a few questions which are 
relevant to the study. Any medication that you are already on will be 
continued as usual. You will be admitted for a day in the in-patient wards of 
the department, and your eye pressure will be measured by two devices, in 
seated position at 10:00am,  2:00pm, 6:00pm, 10:00pm and in seated and 
lying down positions at 2 am and 6 am.  You will be discharged the 
following day, and any further investigations will be done as per 
requirement on out- patient basis. Any change in diagnosis will be 
informed to you, and any change in long-term management plan will be 
instituted immediately.  
Are there any risks for you if you take part in the study?  
As a result of repeated intra-ocular pressure measurements, you may have 
some erosions on the surface of your cornea that may cause discomfort. To 
avoid this you will be administered lubricating eye drops after each IOP 
measurement, and followed-up in the out-patient department till the 
condition heals completely free of cost. We do not expect any long-term or 
serious ocular side-effects as a result of participation in this study, but if 
you do develop any other ocular side effects or problems due to the study, 
these will be treated at no cost to you. However, we are unable to provide 
any monetary compensation.   
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Do you have to pay?  
You will have to pay only for the tests that are required for the routine 
management of your disease. All additional investigations for the study will 
be done free of cost.  
What are the benefits to you if you take part in the study?  
If you participate in the study, you will develop a greater understanding of 
glaucoma and the importance of IOP control.  Also, the adequacy of current 
treatment can be assessed. If the medication you are on or surgery that you 
have undergone is found to be inadequate in controlling your IOP fully, you 
will be referred to glaucoma specialists for adequate revision of medication 
or surgery. This will ultimately help in slowing the progression of disease.  
What are the possible benefits to other people?  
The results of this study may provide benefit to the society in terms of 
advancement of medical knowledge, disease prevention, and therapeutic 
benefit to future patients. We hope that this study will help us determine 
the intra-ocular pressure variation profile in our population, and thereby 
decide an effective protocol for thorough work-up towards a precise 
diagnosis.  
What will happen if I withdraw from the study? 
There will be no adverse consequences of withdrawing from the study and 
there will be no disturbances in your routine eye care. Participation in the 
study is entirely voluntary and you may withdraw at any time. 
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CONSENT FORM 
 
Study title: Diurnal intra ocular pressure profiles in patients with open angle 
glaucoma who have undergone trabeculectomy versus those  on topical 
ocular hypotensive medications 
 
Study Number: ____________ 
 
Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ for the 
above study and have had the opportunity to ask questions. [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being affected. [  ] 
 
(iii)  I understand that the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any further 
research that may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
access. However, I understand that my identity will not be revealed in any information 
released to third parties or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided such a 
use is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Signatory’s Name: _________________________________          
 
Signature:  
 
 
 
 
 
 
 
 
 
 
(Or) 
 
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
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Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name of the Witness: ______________________________ 
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DATA COLLECTION SHEET 
 
Date of examination:                                                      Name: 
 
Study Serial Number :                                                     Age: 
 
Schell Hospital Number :                                               Gender:  
 
CMC Hospital number, if any:                                       Contact number: 
 
Address:                                        
 
 
 
General History  
 
Systemic illness: Diabetes mellitus- Y/N 
                              Hypertension- Y/N 
 
If hypertensive, medications on:  
 
Ocular history:  
 
  
Right eye 
 
Left eye  
 
Primary Ocular diagnosis  
(Type of Open angle glaucoma, phakic 
vs pseudophakic) 
  
 
Treatment given  
( medical or surgical) 
  
 
Details of medication 
(If on topical ocular hypotensive 
medication- name and timings of 
medication) 
  
Current (or most recent) findings (with date):  
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Right eye  
 
Left eye  
 
Visual fields 
  
 
Optic disc findings 
  
Day DVT/ Office hour 
IOP 
  
Central Corneal 
Thickness 
  
 
Diurnal IOP Measurements (corrected) 
 
 RIGHT EYE LEFT EYE 
IOP Tonopen GAT Tonopen GAT 
6 am     
10 am     
2 pm     
6 pm      
10 pm      
2 am     
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EXCEL DATA SHEETS 
 
Obs No.  Gender 
Hosp. 
No. Hypertension 
Type of 
glaucoma 
Treatment 
type 
R Tono 
6 am 
R GAT 6 
am 
L Tono 
6 am 
L GAT 6 
am 
1 2 535519s 1 1 2 12 13 15 17 
2 2 535519s 1 1 1 12 13 15 17 
3 2 547500s 1 2 2 14 15 19 19 
4 2 547500s 1 2 1 14 15 19 19 
5 2 528642s 1 2 1 18 20 13 15 
6 2 528642s 1 2 2 18 20 13 15 
7 1 496653s 2 1 2 7 7 9 9 
8 1 496653s 2 1 2 7 7 9 9 
9 2 500706s 2 1 1 17 20 20 22 
10 2 500706S 2 1 1 17 20 20 22 
11 1 490507s 2 1 2 9 10 16 20 
12 1 448181s 2 1 2 14 16 15 16 
13 1 448181s 2 1 1 14 16 15 16 
14 1 380098s 1 1 1 10 14 10 13 
15 1 380098s 1 1 1 10 14 10 13 
16 1 551981s 1 1 2 13 15 10 11 
17 1 551981s 1 1 1 13 15 10 11 
18 1 496434s 1 1 1 14 14 10 10 
19 1 496434s 1 1 2 14 14 10 10 
20 1 234274s 2 1 1 12 10 10 13 
21 2 563980s 2 1 2 12 10 16 18 
22 2 563980s 2 1 1 12 10 16 18 
23 1 536863s 1 1 1 15 17 18 18 
24 1 536863s 1 1 1 15 17 18 18 
25 2 228372s 2 1 2 21 19 20 20 
26 2 228372s 2 1 2 21 19 20 20 
27 2 542121s 2 1 1 18 20 14 14 
28 2 542121s 2 1 2 18 20 14 14 
29 2 570582s 2 1 1 15 16 11 10 
30 2 570582s 2 1 2 15 16 11 10 
31 2 545885s 2 1 2 9 12 13 16 
32 2 545885s 2 1 1 9 12 13 16 
33 2 477633s 2 1 2 10 12 10 10 
34 2 477633s 2 1 2 10 12 10 10 
35 2 526509s 2 1 2 11 11 12 12 
36 2 526509s 2 1 2 11 11 12 12 
37 1 477919s 1 1 1 12 15 10 13 
38 1 477919s 1 1 1 12 15 10 13 
39 1 516171s 1 1 2 14 12 13 13 
40 1 836674e 1 1 1 19 21 20 22 
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Obs No.  Gender 
Hosp. 
No. 
R Tono 
10 am 
R GAT 
10 am 
L Tono 
10 am 
L GAT 
10 am 
R Tono 
2 pm 
R GAT 2 
pm 
L Tono 
2 pm 
L GAT 2 
pm 
1 2 535519s 14 13 17 19 19 18 12 12 
2 2 535519s 14 13 17 19 19 18 12 12 
3 2 547500s 11 10 13 14 12 13 14 14 
4 2 547500s 11 10 13 14 12 13 14 14 
5 2 528642s 11 13 9 11 18 19 11 13 
6 2 528642s 11 13 9 11 18 19 11 13 
7 1 496653s 7 9 9 11 10 10 10 10 
8 1 496653s 7 9 9 11 10 10 10 10 
9 2 500706s 9 12 13 14 11 13 15 16 
10 2 500706S 9 12 13 14 11 13 15 16 
11 1 490507s 10 12 18 20 12 15 19 21 
12 1 448181s 12 14 16 18 9 11 16 16 
13 1 448181s 12 14 16 18 9 11 16 16 
14 1 380098s 12 13 10 11 9 14 11 15 
15 1 380098s 12 13 10 11 9 14 11 15 
16 1 551981s 11 13 10 11 14 16 16 17 
17 1 551981s 11 13 10 11 14 16 16 17 
18 1 496434s 18 20 12 10 22 21 11 12 
19 1 496434s 18 20 12 10 22 21 11 12 
20 1 234274s 8 12 7 10 11 14 14 15 
21 2 563980s 11 10 14 14 12 12 14 16 
22 2 563980s 11 10 14 14 12 12 14 16 
23 1 536863s 19 20 18 20 16 16 16 17 
24 1 536863s 19 20 18 20 16 16 16 17 
25 2 228372s 17 17 21 18 11 10 15 17 
26 2 228372s 17 17 21 18 11 10 15 17 
27 2 542121s 20 20 16 14 16 16 14 14 
28 2 542121s 20 20 16 14 16 16 14 14 
29 2 570582s 14 15 11 13 12 13 12 10 
30 2 570582s 14 15 11 13 12 13 12 10 
31 2 545885s 12 16 15 18 11 14 10 13 
32 2 545885s 12 16 15 18 11 14 10 13 
33 2 477633s 12 12 14 12 10 13 12 12 
34 2 477633s 12 12 14 12 10 13 12 12 
35 2 526509s 10 10 12 12 14 12 10 10 
36 2 526509s 10 10 14 12 14 12 10 10 
37 1 477919s 7 11 6 12 14 13 15 14 
38 1 477919s 7 11 6 12 14 13 15 14 
39 1 516171s 12 12 14 14 14 12 13 15 
40 1 836674e 17 18 14 16 15 18 15 17 
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Obs No.  Gender 
Hosp. 
No. 
R Tono 
6 pm 
R GAT 6 
pm 
L Tono 
6 pm 
L GAT 6 
pm 
R Tono 
10 pm 
R GAT 
10 pm 
L Tono 
10 pm 
L GAT 
10 pm 
1 2 535519s 12 12 18 18 14 14 17 18 
2 2 535519s 12 12 18 18 14 14 17 18 
3 2 547500s 12 12 12 14 11 12 14 16 
4 2 547500s 12 12 12 14 11 12 14 16 
5 2 528642s 14 15 9 9 13 14 9 9 
6 2 528642s 14 15 9 9 13 14 9 9 
7 1 496653s 9 9 10 10 7 8 8 10 
8 1 496653s 9 9 10 10 7 8 8 10 
9 2 500706s 14 15 17 16 14 11 14 14 
10 2 500706S 14 15 17 16 14 11 14 14 
11 1 490507s 11 14 17 20 10 12 18 18 
12 1 448181s 15 16 18 18 10 13 12 14 
13 1 448181s 15 16 18 18 10 13 12 14 
14 1 380098s 11 11 9 12 13 17 13 16 
15 1 380098s 11 11 9 12 13 17 13 16 
16 1 551981s 11 16 13 18 15 18 13 16 
17 1 551981s 11 16 13 18 15 18 13 16 
18 1 496434s 18 16 10 10 14 14 8 10 
19 1 496434s 18 16 10 10 14 14 8 10 
20 1 234274s 10 12 11 12 8 11 10 13 
21 2 563980s 10 11 12 14 12 10 12 12 
22 2 563980s 10 11 12 14 12 10 12 12 
23 1 536863s 16 18 16 18 14 16 14 14 
24 1 536863s 16 18 16 18 14 16 14 14 
25 2 228372s 16 16 17 15 18 20 18 20 
26 2 228372s 16 16 17 15 18 20 18 20 
27 2 542121s 16 16 16 16 16 18 14 16 
28 2 542121s 16 16 16 16 16 18 14 16 
29 2 570582s 12 12 11 12 13 15 12 10 
30 2 570582s 12 12 11 12 13 15 12 10 
31 2 545885s 10 12 9 10 10 15 9 13 
32 2 545885s 10 12 9 10 10 15 9 13 
33 2 477633s 10 11 11 13 12 14 14 12 
34 2 477633s 10 11 11 13 12 14 14 12 
35 2 526509s 10 12 11 13 13 13 10 11 
36 2 526509s 10 12 11 13 13 13 10 11 
37 1 477919s 11 11 13 14 11 14 13 15 
38 1 477919s 11 11 13 14 11 14 13 15 
39 1 516171s 10 14 14 12 12 12 13 14 
40 1 836674e 16 16 16 16 17 18 16 19 
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Obs No.  Gender 
Hosp. 
No. 
R tono 
2 am 
R GAT 2 
am 
L Tono 
2 am 
L GAT 2 
am 
1 2 535519s 15 18 17 20 
2 2 535519s 15 18 17 20 
3 2 547500s 12 14 18 14 
4 2 547500s 12 14 18 14 
5 2 528642s 19 21 13 13 
6 2 528642s 19 21 13 13 
7 1 496653s 6 8 8 10 
8 1 496653s 6 8 8 10 
9 2 500706s 18 21 20 22 
10 2 500706S 18 21 20 22 
11 1 490507s 11 13 19 21 
12 1 448181s 10 12 12 14 
13 1 448181s 10 12 12 14 
14 1 380098s 11 15 11 14 
15 1 380098s 11 15 11 14 
16 1 551981s 11 15 11 15 
17 1 551981s 11 15 11 15 
18 1 496434s 10 12 8 8 
19 1 496434s 10 12 8 8 
20 1 234274s 10 10 11 14 
21 2 563980s 10 12 14 12 
22 2 563980s 10 12 14 12 
23 1 536863s 16 16 14 16 
24 1 536863s 16 16 14 16 
25 2 228372s 18 18 16 14 
26 2 228372s 18 18 16 14 
27 2 542121s 18 20 16 18 
28 2 542121s 18 20 16 18 
29 2 570582s 16 18 10 10 
30 2 570582s 16 18 10 10 
31 2 545885s 10 11 11 14 
32 2 545885s 10 11 11 14 
33 2 477633s 14 14 12 12 
34 2 477633s 14 14 12 12 
35 2 526509s 14 12 12 10 
36 2 526509s 14 12 12 10 
37 1 477919s 11 11 11 12 
38 1 477919s 11 11 11 12 
39 1 516171s 13 14 15 14 
40 1 836674e 19 20 14 18 
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